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The investigation of cerebral microcirculation is challenging due to the 
complex three-dimensional structure of the brain and the requirement to maintain 
subject physiology to ensure an adequate blood supply. We developed an algorithm to 
capture blood flow dynamics with high temporal and spatial resolution when coupled 
with two-photon excited fluorescence microscopy imaging. Using these techniques 
and chronic craniotomy surgical preparations, we focused our attention on 
myeloproliferative neoplasms and their impacts on cortical circulation. These 
rheological conditions exhibit an excessive amount of red blood cells, leukocytes, 
and/or platelets, resulting in abnormal, prothrombotic flow conditions. Although no 
direct evidence has indicated microvascular flow disruptions in the brain, cognitive 
dysfunction is reported among myeloproliferative neoplasm patients. Because 
neurological impairment is linked to cerebral microcirculation problems, we looked 
for direct confirmation in animal models of the diseases—essential thrombocythemia 
and polycythemia vera, specifically. We found cerebral microvessels in the subjects to 
be largely occluded by leukocytes and platelets, which adhered tightly to the 
endothelium. In the case of essential thrombocythemia, ~20% of the stalled vessels by 
 platelets remain blocked for over two hours, while the rest of the micro-occlusions 
resolved and reestablished flow on their own. The adherence of leukocytes and 
platelets is a result of cellular activation due to enhanced cell-to-cell interactions in the 
high hematocrit flow regime as well as the triggering of platelet aggregation by injured 
endothelial cells. We concluded that there is a need for targeted therapy to resolve 
cerebral microcirculation disruption, and that clinicians should include a careful 
cognitive evaluation when treating patients with myeloproliferative neoplasms. In 
future work, we are interested in identifying the mechanism of thrombosis in sickle 
cell disease where patients are severely anemic but prone to thrombosis, nevertheless. 
 
Two-photon excited fluorescence microscopy also has many other 
applications. We exercised one by using second harmonic generation imaging to 
observe collagen fibers in cardiac tissue in vitro. In this study, collagen fibers were 
presented with cyclic anisotropic strain that led to tissue alignment and remodeling. 
We identified that anisotropy of biaxial strain causes fiber alignment along the 
principal directions of strain and concluded that strain field anisotropy is an 
independent regulator of fibroblast cell phenotype, turnover, and reorganization. 
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CHAPTER 1 
INTRODUCTION AND ORGANIZATION OF DISSERTATION 
  
 2 
INTRODUCTION 
Investigation of cerebral microcirculation presents many technical challenges 
to researchers. First, it requires in vivo observation where subjects can maintain a 
blood flow level comparable to that of physiological conditions of interest. In addition, 
the technique must have a reasonably high temporal and spatial resolution to 
determine dynamics and characteristics of the flow. Traditionally, microcirculatory 
systems of choice were limited to 2-dimensional systems, such as the mesenteric 
tissues and cremaster muscles, due to limited depth penetration of available imaging 
modalities. The brain, however, is a complex, 3-dimensional organ. With the 
introduction of two-photon excited fluorescence microscopy, we are able to observe 
blood flow in individual cortical microvessels from the surface of the brain to 1-mm 
beneath. Animals can be observed over hours, days, and weeks when coupled with 
chronic surgical preparations. The technique has immensely expanded the 
neurological disorders research field and enhanced the quality of the studies. 
 
In this dissertation, we focus on hematological disorders, specifically 
myeloproliferative neoplasms, and their impact on cerebral microcirculation. Animal 
models of myeloproliferative neoplasms are recently available; therefore, prior studies 
were limited to clinical data. In addition, the brain was overlooked because 
myeloproliferative neoplasms are regarded as blood disorders, not brain disorders. 
However, one prominent feature of these disorders is thrombosis and circulation 
problems. Nevertheless, evidence suggests that patients with myeloproliferative 
neoplasms present neurological deficits. Because problems with microcirculation in 
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the brain such as small strokes are known to be associated with cognitive decline, 
dementia, and Alzheimer’s disease, we suspect that alterations in blood rheology 
would result in abnormal circulation in microvascular networks that can lead to 
cognitive problems. Therefore, we examine cerebral blood flow in myeloproliferative 
neoplasms, while accounting for mechanisms that may be common aspects of bad 
blood flow that lead to neurological disorders. 
 
ORGANIZATION OF DISSERTATION 
The work described in this dissertation includes the development of in vivo, 
high spatio-temporal resolution imaging technique to study cerebral hemodynamics in 
normal and pathological states. The methods were utilized to examine the effects of 
myeloproliferative neoplasms and sickle cell disease—both hematological disorders—
on cortical microcirculation. In addition, we made use of second harmonic generation 
using two-photon excited fluorescence microscopy to examine collagen rearrangement 
under cyclic strain. Each chapter can be read independently. 
 
Chapter 2:  This chapter introduces readers to non-linear optical imaging method, 
specifically two-photon excited fluorescence microscopy. It describes fluorescence 
generation, including second harmonic generation, and a brief overview of microscope 
setup. Two-photon excited fluorescence microscopy was compared to other 
microvascular flow measurement techniques, and its application to brain research was 
discussed. 
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Chapter 3:  This chapter gives a background on myeloproliferative neoplasms. It 
describes the pathogenesis and genetics of the hematological conditions that alter 
blood compositions. The mechanisms and rheological impacts, especially thrombosis 
in microcirculatory systems, clinical outcomes, and current treatments were discussed. 
Myeloproliferative neoplasms effects on the brain were studied in details later in 
chapter 5.  
 
Chapter 4:  Subtle alterations in cerebral blood flow can impact the health and 
function of brain cells and are linked to cognitive decline and dementia. To understand 
hemodynamics in the three-dimensional vascular network of the cerebral cortex, we 
applied two-photon excited fluorescence microscopy to measure the motion of red 
blood cells in individual microvessels throughout the vascular hierarchy. We 
developed an algorithm to resolve cortical blood flow with high temporal and spatial 
resolution, and found flow pulsatility dependency on cardiac and respiration rhythms 
even in smallest capillaries and venules   
 
Chapter 5:  Myeloproliferative neoplasms are a group of hematological diseases 
where the bone marrow is overactive, resulting in excess red blood cells, white blood 
cells, and platelets. These additional cellular components of the blood lead to high 
viscosity, endothelial activation, and prothrombotic environment. To date, direct 
visualization of cerebral microcirculatory problem in vivo has not been done because 
of the lack of animal model and advanced imaging technique. We used two-photon 
excited fluorescence microscopy to investigate microvascular network and found 
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occlusions of individual capillaries of MPN mice. These blood flow disruptions are 
associated with leukocyte and platelet plugs and were negligibly affected by the 
standard aspirin treatment. 
 
Chapter 6:  Sickle cell disease is a genetic disorder where red blood cells become 
abnormal, rigid, sickle shape upon deoxygenation. Sickling leads to various 
complications including increased vascular resistance, occlusions of blood vessels, and 
red blood cell breakage resulting in anemia. In this chapter, we observed transition of 
red blood cell physiology and flow characteristics in cerebral microvessels of mouse 
models of sickle cell disease under a variety of oxygen levels. 
 
Chapter 7:  Connective tissues in heart valve leaflets have evolved to perform critical 
biomechanical functions under cyclic loading. These tissues are composed of 
collagenous fibers, oriented to optimize anisotropic mechanical properties appropriate 
to their local environment. The organized structure is created and modified by resident 
fibroblasts in response to mechanical forces in their environment, but the effect of 
strain direction on matrix remodeling is unclear. In this chapter, we designed a 
bioreactor system capable of generating and maintaining anisotropic strain on 
fibroblast in three-dimensional hydrogel. The collagen realignment in response to the 
stimulus force was verified using second harmonic imaging microscopy. 
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Chapter 8:  This chapter summarizes important findings from previous chapters. It 
also discusses impacts in the clinical setting and future directions of cerebral 
microcirculatory research in hematological disorders.  
7 
CHAPTER 2 
ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA 
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Myeloproliferative neoplasms (MPNs) are rheological disorders that result 
from hyperactivity of the bone marrow, leading to an increase in various cellular 
components of the blood. There are four types of MPN disorders; polycythemia vera 
(PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), and chronic 
myelogenous leukemia (CML) (1). An acquired mutation (JAK2) in hematopoietic 
stem cells is common in the MPNs, and leads to abnormal proliferation of various 
blood cells. In PV, red blood cells (RBCs), white blood cells (leukocytes), and 
platelets production is enhanced, leading to excess in the cellular components of the 
blood. Platelet and leukocyte counts are elevated in ET and CML, respectively. Lastly, 
PMF usually presents with complete blood counts similar to those of PV or CML, but 
progresses to thrombocytopenia and anemia over time. All the MPNs are characterized 
by blood flow and/or coagulation problems, which occur in diminishing order of 
severity and frequency in PV, ET, PMF, and (rarely) CML. Phlebotomy, cytoreductive 
therapy, low-dose aspirin, and JAK2 inhibitors are often employed to correct blood 
counts, reduce hypercoaguability, and restore normal blood flow. 
 
Thrombotic events are common in PV and ET. In fact, stroke, cardiovascular 
diseases, and deep-vein thrombosis are the main causes of morbidity and mortality in 
these conditions. Alterations in the blood result in abnormal rheology, including 
increased whole blood viscosity and resistance, disproportional expansion of cell mass 
in vascular lumen, and enhanced interactions between platelets, leukocytes, RBCs, and 
endothelium. Although disturbance in small vascular networks is suspected, no direct 
studies have focused on microcirculatory systems due to the lack of animal models of 
9 
MPNs and advanced tools to visualize blood flow in vivo. Meanwhile, evidence of 
neurological complications in patients with ET and PV indicates a need to understand 
the impacts of these diseases on cerebral hemodynamics. Therefore, this chapter 
reviews ET and PV and serves as a basis for our study in Chapter 5 of the impacts of 
MPNs on cortical blood flow. 
 
JAK2V617F MUTATION AND MYELOPROLIFERATIVE NEOPLASMS 
 JAK2 is a cytoplasmic tyrosine kinase in the signal transducer and activators of 
transcription (STAT) signaling pathway in hematopoietic stem cells. The acquired 
somatic point mutation at codon 617 of the JAK2 gene leads to a valine-to-
phenylalanine mutation in this kinase. Although found in patients with all MPNs, 
JAK2V617F mutation is most common in ET (60% of the cases) and PV (95% of the 
cases) (2). Normally, STAT molecules are phosphorylated by activated JAK2, then 
translocate to the nucleus, promoting production of blood cells including RBCs, 
leukocytes, and platelets. The V617F mutation in JAK2 leads to constitutive 
phosphorylation activity and the recruitment of STAT molecules, leading to 
unregulated production of blood cells (Fig. 2.1) (3, 4). 
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Figure 2.1:  JAK/STAT signal transduction pathway in responses to 
hematopoietic growth factors 
Under normal conditions (A), erythroid and megakaryocytic progenitors require 
binding of erythropoietin (Epo) or thrombopoietin (Tpo) to their respective 
receptors (Epo-R or Tpo-R) to initiate the intracellular sequence of 
phosphorylation and activation events, leading to transcriptional activation of 
growth factor-responsive target genes. In hematopoietic progenitor cells of patients 
with MPNs who have the JAK2V617F mutation (B), this JAK/STAT signal 
transduction pathway is constitutively activated in the absence of binding of 
erythropoietin or thrombopoietin to their respective receptors (5).  
JAK2 mutation in the MPDs
JAK2, like the other members of the JAK family, has an enzymati-
cally active kinase domain (JH1) and a catalytically inactive
pseudokinase domain (JH2). The JH2 domain has an autoinhibitory
function that normally suppresses the kinase activity of JAK2.22
The mutation recently described in the classic MPDs by several
groups23-28 is a guanine-to-thymine mutation encoding a valine-to-
phenylalanine substitution at position 617 (V617F) in the JH2
domain of JAK2. It is a gain-of-function mutation in that it releases
the autoinhibitory action of JH2 and thereby results in expression
of a constitutively activated JAK2 tyrosine kinase. JAK2-V617F
may thus bind to a receptor (eg, Epo-R or Tpo-R) and recruit STATs
in the complete absence or in the presence of only trace quantities
of hematopoietic growth factor (eg, Epo or Tpo)29 (Figure 1).
Several lines of evidence indicate that JAK2-V617F has a causal or
contributory role in the pathogenesis of the MPDs and is not simply a
passenger mutation that arose coincidentally in the same stem cell. A
short interfering RNA(siRNA) to knockdown JAK2 expression blocked
endogenous erythroid colony formation in cells from PV patients with
the JAK2-V617F mutation.23 Expression of the mutated JAK2 (but not
wild-type JAK2) induced Epo hypersensitivity and Epo-independent
survival of cultured cell lines in vitro.23,24,26 The in vivo effect of the
mutation was demonstrated by the development of erythrocytosis in
mice that received transplants with bone marrow containing the
JAK2-V617F mutation, but not wild-type JAK2.23
As shown in Table 2, all of the recently published studies
showed that the majority of patients with PV (65%-97%) have
the JAK2-V617F.23-28 In contrast, only 23% to 57% of patients
with ET have the JAK2 mutation.23-26,28 Kralovics et al provided
clinical correlations and reported that patients with JAK2-
V617F had a significantly longer duration of disease, more
treatment with cytoreductive agents, and higher rates of compli-
cations (myelofibrosis, thrombosis, and bleeding) than did those
with wild-type JAK2.26
Several other biologic and epigenetic markers have been
previously described in a variable number of patients with PV
and ET. These include deregulated expression of Bcl-x, an
inhibitor of apoptosis,30 overexpression of the PRV-1 and
transcription factor NF-E2 genes,31,32 and impaired expression
of Tpo-R.33 No mutations have yet been detected in these genes,
and recent evidence indicates that altered expression of these
markers is due to activation of the JAK/STAT pathway through
the JAK2-V617F mutation.34 Therefore, abnormal expression of
these molecules appears to be a secondary consequence of the
primary JAK2 mutation.25
Molecular reclassification of the MPDs
The discovery of the JAK2-V617F mutation is a major break-
through in understanding the molecular pathogenesis of the classic
MPDs. However, it will be important to determine the reasons why
(1) there is such phenotypic pleiotropy in patients with apparently
different MPDs with the same disease allele and (2) not all patients
demonstrate this mutation. Several explanations are possible. It is
possible that the mutation arises only in specific subpopulations of
primitive hematopoietic progenitor cells or has biochemical proper-
ties that restrict its activity to cells of a specific lineage(s).19 The
recent observation that expression of JAK2-V617F in mouse bone
marrow results in polycythemia in different strains, but that
associated leukocytosis is strain-dependent, suggests that genetic
modifiers affect the hematopoietic phenotype of the JAK2 muta-
tion.35 Disease alleles other than JAK2-V617F might be involved,
particularly involving other tyrosine kinases; however, Levine et
al24 failed to identify any mutations by exon sequence analysis of
the activating loops and autoinhibitory domains of other tyrosine
kinases from granulocyte DNA samples from PV patients. Other
mutations may occur36 in pathways that interact with JAK/STAT
signaling or in other effector proteins, including adapter molecules
Figure 1. JAK/STAT signal transduction pathway in
responses to hematopoietic growth factors. Under
normal conditions (A), erythroid and megakaryocytic
progenitors require binding of erythropoietin (Epo) or
thrombopoietin (Tpo) to their respective receptors (Epo-R
or Tpo-R) to initiate the intracellular sequence of phosphor-
ylation and activation events leading to transcriptional
activation of growth factor–responsive target genes (de-
tails presented in “Molecular mechanisms of PV and ET”).
In hematopoietic progenitor cells of patients with MPDs
who have the JAK2-V617F mutation (B), this JAK/STAT
signal transduction pathway is constitutively activated in
the absence of binding of Epo or Tpo to their respective
receptors.
Table 2. JAK2 mutation in the MPDs
Study PV ET MMM
James et al23 40/45 (89) 9/21 (43) 3/7 (43)
Levine et al24 121/164 (74) 37/115 (32) 16/46 (35)
Baxter et al25 71/73 (97) 29/51 (57) 8/16 (50)
Kralovics et al26 83/128 (65) 21/93 (23) 13/23 (57)
Zhao et al27 20/24 (83) — —
Jones et al28 58/72 (81) 24/59 (41) 15/35 (43)
Total 393/506 (78) 120/339 (35) 55/127 (43)
Values in the data field represent proportion of patients positive for the JAK2
mutation, with the percentage in parentheses.
— indicates no data.
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Additional research is required to answer how a common JAK2 mutation can 
lead to a variety of MPN phenotypes. In mice, retroviral delivery of mutant JAK2V617F 
resulted in development of both ET and PV phenotypes. A higher level of mutant 
JAK2 gene leads to elevated RBC, leukocyte, and platelet counts, whereas a lower 
level of the gene leads to elevated platelet counts similar to ET (6). Likewise, while 
the JAK2V617F mutation is generally more frequent in human cases of PV, only 60% of 
ET cases possess the JAK2V617F mutation. Therefore, several hypotheses have been 
developed to address the variation in phenotypes associated with the mutant JAK2 
gene. One theory is gene dosage: 25% of patients with PV carry 2 copies of 
JAK2V617F, compared to mostly heterozygous or wildtype ET patients. Observations in 
mouse models of MPN are highly consistent with the gene dosage theory. 
Alternatively, it is possible that additional mutations may be involved in the 
pathogenesis of these diseases. In this theory, hematopoietic stem cells of myeloid 
lineage acquire JAK2V617F. Since virtually all PV cases carry this mutation, JAK2V617F 
alone may lead to disease progression. Perhaps, in order for ET or PMF to develop, a 
secondary mutation must occur in addition to the JAK2V617F. This hypothesis seems 
reasonable, as hematopoietic malignancies often bear more than one mutated gene. 
Finally, receptor expression may influence the level of JAK2V617F activation. Many 
receptors, including erythropoietin and thrombopoietin receptors, are expressed during 
myeloid and erythroid differentiation. The interaction between these receptors and 
JAK2V617F may influence the expression of the activated phenotype (Fig. 2.2) (7). 
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Figure 2.2:  Possible causes of phenotype variability exhibited by JAK2V617F 
(a) Gene dosage. Heterozygous contribution of JAK2V617F may lead to essential 
thrombocythemia. Homozygous contribution and a lack of wild-type JAK2 may lead 
to more severe phenotypes, such as PV and PMF. (b) Unidentified mutations. 
JAK2V617F or other mutations can lead to essential thrombocythemia. However, 
JAK2V617F is required for phenotypes such as PV, with secondary mutations needed 
for the progression to PMF. (c) Specific receptors are expressed on the surface of 
myeloid cells. The type of receptor may result in higher levels of JAK2V617F activation 
that influence the phenotype of disease (8). 
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Figure 3
Causes of phenotype variability exhibited by JAK2V617F. (a) Gene dosage. Heterozygous contribution of
JAK2V617F may lead to essential thrombocythemia. Homozygous contribution and a lack of wild-type
(WT) JAK2 may lead to more severe phenotypes, such as polycythemia vera (PV) and idiopathic
myelofibrosis (IMF). (b) Unidentified mutati ns. JAK2V617F or other mutations can lead to essential
thrombocythemia. However, JAK2V617F is required for phenotypes such as PV, with secondary
mutations needed for the progression to IMF. (c) Specific receptors are expressed on the surface of
myeloid cells. The type of receptor may result in higher levels of JAK2V617F activation that influence
the phenotype of disease.
for stronger interactions with JAK2V617
(Figure 3c), the affected cell populations may
be activated to varying degrees.
THERAPIES AND FUTURE
RESEARCH
Although questions still remain concerning
the role and functional consequences of the
JAK2V617F mutation, its discovery has led
to the reevaluation of treatments for myelo-
proliferative diseases. Clearly, with the recog-
nition of this mutation, MPDs can now be
viewed as stem cell disorders rather than re-
active conditions, although its presence alone
cannot distinguish PV from ET or IMF. Un-
derstanding the molecular pathogenesis of
diseases—for example, knowing the role of
BCR-ABL in CML and now JAK2 617F in
PV and some cases of ET and IMF—has
laid the foundation for investigating small-
molecule inhibitors for JAK2. Current JAK2
inhibitors have shown promise by reducing
growth of JAK2V617F-positive cell lines and
primary cells (14, 31, 38); thus, efforts are
ongoing to develop compounds for clinical
use. However, it is not known whether an in-
hibitor can show specific activity against the
mutant without disrupting wild-type JAK2
and causing significant hematological toxicity.
Costmanagementmay become an even larger
issue, since most conventional therapies are
www.annualreviews.org • JAK2 and Myeloproliferative Diseases 377
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CLINICAL COMPLICATIONS IN ET AND PV 
Hemorrhagic and thrombotic complications are the major causes of morbidity 
and mortality in ET and PV. In general, the use of antiplatelet drugs (e.g. aspirin) in 
MPNs increases the risk of bleeding. But, counterintuitively, the risk of bleeding is 
also heightened in cases of extreme thrombocytosis, especially in patients with ET (9, 
10). The vast number of platelets may sequester von Willebran factors in the blood 
stream and prevent them from aiding normal adhesion of platelets to wound sites, 
resulting in abnormal bleeding (11). 
 
Coagulation and circulation problems in ET and PV are abundant, leading to a 
number of secondary clinical conditions with a wide range of severity. Some of the 
more minor manifestations include fatigue, shortness of breath, dizziness, headache, 
and pluritus; other major ones are deep vein thrombosis of the lower extremities (9, 
12), pulmonary embolism, erythromelalgia (13), edema, heart attack (14), and 
stroke(15). During and after surgical procedures, even when coupled with heparin 
treatment, arterial and venous thrombotic events frequently develop in MPN patients 
(16). These symptoms are rooted in thrombotic complications due to the abnormal 
rheology associated with excess RBCs, leukocytes, and/or platelets. 
 
In PV, high hematocrit is the most influential factor governing occurrences of 
thrombotic events (17). The physical consequences of red-cell mass expansion include 
increased strain on the vessel wall due to hyperviscosity, increased shear stress 
experienced by blood cells, and vasoconstriction due to nitric oxide scavenging by 
14 
RBCs (18). The elevated shear stress on the vessel wall leads to endothelial damage 
and activation in addition to platelets and leukocytes activation, enhancing cell-cell 
and cell-endothelium interactions (9, 19). This environment is highly prothrombotic 
and is commonly observed in cases of PV with high hematocrit (17). Since viscosity 
increases exponentially as hematocrit increases, it is important to tightly control 
hematocrit level (Fig. 2.3) (18). The use of phlebotomy to reduce hematocrit has been 
shown to restore blood flow in PV patients (20). Unfortunately, reduction in RBC 
mass is only part of the answer. Even among PV patients with same hematocrit level, 
viscosity varies widely (21). In addition, the pathological effects of elevated 
hematocrit may relate to reduced endothelial surface layer thickness and the 
consequent alteration in the blood–endothelium interface that further increases flow 
resistance (22). The roles of leukocytes and platelets in abnormal coagulation have 
also been examined. PV patients with high leukocyte count (above 15 x 109/L) had an 
increased risk for thrombotic events, mainly derived from an increased risk of 
myocardial infarction (23) Platelets did not play a statistically significant role in 
influencing thrombotic risk, however (24) The reason for this is unknown at the 
present. 
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Figure 2.3:  Mechanisms of Thrombosis in Polycythemia Vera 
Microvascular thrombosis (A) involves the interaction of activated platelets and 
endothelial cells, which is facilitated by the high shear rate, especially in arterioles. 
Macrovascular thrombosis (B) takes place in larger vessels where the effects of an 
elevated red-cell mass on blood flow are most pronounced. With the expansion of red-
cell mass, laminar flow is disturbed, vessel-wall strain is increased, and the 
interactions of platelets and leukocytes with the endothelium, RBCs, and each other 
are enhanced. Thus, even in a situation in which blood viscosity leads to low shear 
rates, platelet adhesion and aggregation are facilitated, and thrombin generation is 
initiated. (C) The relation between the blood viscosity and the hematocrit. The relation 
between thrombosis and the hematocrit in PV follows a similar curve, underscoring 
the fact that the expansion of the red-cell mass, rather than abnormal platelets or 
leukocytes, that dominates the mechanism of coagulopathy associated with this 
disorder (18)  
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Figure. Mechanisms of Thrombosis in Polycythemia Vera.
 
Microvascular thrombosis (Panel A) involves the interaction of activated platelets and endothelial cells in arterioles through the adhesive pro-
teins P-selectin, glycoprotein Ib
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, and von Willebrand factor, which is facilitated by the high shear rate in these vessels, with thrombus forma-
tion in the absence of substantial fibrin generation. Macrovascular thrombosis (Panel B) takes place in larger vessels where the effects of an 
elevated red-cell mass on blood flow are most pronounced. With the expansion of red-cell mass, laminar flow is disturbed, vessel-wall strain 
is increased, and the interactions of platelets and leukocytes with the endothelium, red cells, and each other are enhanced. Thus, even in a sit-
uation in which blood viscosity leads to low shear, platelet adhesion and aggregation are facilitated, and thrombin generation is initiated. Pan-
el C shows the relation between the blood viscosity and the hematocrit. The relation between thrombosis and t e hematocrit in polycythemia 
vera follows a similar curve, underscoring the fact that it is the expansion of the red-cell mass, rather than abnormal platelets or granulocytes, 
that leads to th  coagulopathy associated with this disorder.
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On the other hand, the story of thrombosis in ET is rather confounding. 
Naturally, platelet and leukocyte counts have been the main target of plentiful studies. 
Leukocytosis increases thrombotic events and is an independent predictor of leukemic 
transformation in ET (25, 26) The role of platelets, however, was not shown to 
increase thrombotic risk in ET consistently, except at extremely high levels (above 
1500 x 109/L) (9, 10). Since platelet cytoreduction therapy reduces thrombotic event in 
high-risk patients, the present school of thought is that thrombocytosis indirectly 
contributes to the hemostatic complications of ET.  
 
The prothrombotic flow regime in ET and PV is detrimental to adequate 
microcircular transport of nutrition, waste, and oxygen, which are crucial to 
maintaining neural health. Low levels of erythropoietin common among PV patients 
may also contribute to a worsened infarct outcome due to the lack of its 
neuroprotective properties (27). Neurological complications of ET and PV include 
depression (28, 29), mixed movement disorder (29), amnesia, headache, and 
dysphagia (30). Stroke and cerebral embolism are also prevalent in both ET (31) and 
PV (32), observations which are also consistent with our own, as later described in 
Chapter 5.  
 
CELLULAR ACTIVATION AND INTERACTIONS  
Thrombosis is a result of the complex interplay between activated platelets, 
leukocytes, and vascular endothelial cells. In MPNs, first, platelets adhere to the 
damaged endothelium. The adhesion event triggers the activation of these platelets and 
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the release of activating factors stored in their granules, including membrane ligands 
and chemokines, which recruit leukocytes as well as additional platelets to the vessel 
wall. The adherence of leukocytes to the vessel wall is mediated by adherent platelets 
via P-selectin (33) P-selectin, a cell-adhesion molecule, is expressed by activated 
platelets and primarily mediates initial interactions between platelets and leukocytes 
via P-selectin glycoprotein ligand-1 (PSGL-1), which is constitutively expressed on 
leukocyte surfaces (34). 
 
Overactivation of leukocytes and platelets in PV and ET has been observed 
both in vivo and in vitro (13). The leukocytes in ET and PV overexpress CD11b, an 
antigen mediating adhesion during inflammation. These leukocytes thus have a greater 
capacity for phagocytosis as well as increased production of reactive oxygen species 
(35). Further, in ET patients with thrombotic events, the expression of CD11b in 
monocytes and the percentage of platelets expressing P-selectin is increased in 
comparison to ET patients without thrombotic events. Similarly, CD11b expression is 
significantly increased in neutrophils when comparing PV patients with and without 
thrombosis. This suggests that leukocyte activation in MPNs plays an essential role in 
thrombogenesis. ET patients are also more likely to show increases in E-selectin and 
circulating microparticles, both of which amplify thrombogenesis (36, 37). Further, 
prothrombin fragment, thrombomodulin, and von Willebrand factor were found to be 
elevated in both PV and ET. Platelet and leukocyte activation results in an increased 
percentage of circulating platelet-leukocyte complexes, which is reported to correlate 
with neutrophil degranulation, stabilization of fibrinogen, and higher extracellular 
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tissue factor content (38, 39). Hence, prothrombotic flow environment is constituted 
(37, 40, 41). And indeed, high leukocyte count correlates to high thrombotic incidence 
in ET patients (25, 42). Our observations of both leukocyte and platelet adhesion to 
microvasculature and obstruction of blood flow, as described in Chapter 5, is also in 
agreement with clinical findings. 
 
 The JAK2V617F mutation seems to play its prothrombotic role by encouraging 
P-selectin overexpression. P-selectin was found to be higher in ET patients with the 
mutation compared to patients with wild-type allele (38). Interestingly, the dosage 
effect of JAK2V617F allelic burden on levels of coagulation players including soluble P-
selectin, soluble CD40 ligand, von Willebrand factor, and circulating platelet-
leukocyte complexes was observed in JAK2V617F positive ET patients. JAK2V617F also 
promotes leukocyte overactivation, and therefore also correlates with increased 
adhesion, endothelial damage, and high coagulation incidence in ET (25). 
 
In our study, we found blood brain barrier leakage into the parenchymal tissue, 
likely due to vascular damage. This is consistent with the severe endothelial damage 
that has been seen using electron microscopy (43). Increased circulating endothelial 
cells indicating endothelial activation has also been previously detected (36). The 
endothelial dysfunction and enhanced cellular adhesion results in chronic obstructions 
of the cerebral microcirculation. 
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The consequence of high thrombotic incidence in the brain is our particular 
interest. Hyperviscosity, endothelial injury due to leukocyte activation, thrombus 
formation, and hyperactivated JAK2 are all features characteristic of ET and PV that 
may contribute, along with other risk factors, to the development and progression of 
atherothrombosis (14). Endothelial dysfunction has been identified to be involved in 
the pathogenesis of lacunar stroke, especially in those patients with concomitant silent 
lacunar infarcts and ischemic white matter lesions (15, 44). Several studies have also 
linked inflammatory factors—soluble P-selectin, surface P-selectin expression, and 
platelet-leukocyte aggregates in blood—to patients with arterial thrombosis, including 
cerebrovascular events (45). Therefore, we focused our study in the brain of MPN 
mouse models. And we have found direct evidence of small stroke in capillary beds. 
For this reason, clinical treatments should pay careful attention on cognitive health and 
function of MPN patients. 
 
MANAGEMENT OF ET AND PV 
 Current therapy for ET and PV is not curative. The objective is to prevent 
thrombotic and hemorrhagic events and to minimize splenomegaly. Phlebotomy, 
targeting a normal physiological hematocrit of ~45%, is the dominant method for 
correcting excessive RBCs in PV (46). Aspirin is also used in both ET and PV to 
reduce platelet adherence except in cases where the patient is at risk for hemorrhage 
(4). Available cytoreductive therapy includes hydroxyurea, busulfan, anagrelide, and 
interferon-alpha (INF-α) (Table 2.1), the last of which also acts as a myelosuppresant 
(4). Hydroxyurea is the most commonly prescribed as it provides the best 
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hematological outcome with the least adverse effects. When compared to other 
available cytoreductive therapies, hydroxyurea is associated with significantly lower 
risk of arterial thrombosis, major hemorrhage, and myelofibrosis transformation. Its 
dose is titrated to keep platelets lower than 400 x 109 /L and leukocytes higher than 2 x 
109 /L.  For patients who are intolerant or resistant to hydroxyurea, INF-α or busulfan 
are employed. However, both drugs are less widely used, since their side effects are 
generally more severe compared to hydroxyurea and their long-term effects are still 
unknown. Lastly, anagrelide is superior to hydroxyurea in preventing venous 
thrombosis. There is a notion among physicians that hydroxyurea and anagrelide are 
leukemogenic. However, hydroxyurea is an effective long-term treatment for sickle-
cell disease and does cause leukemia in those patients (47). Therefore, this claim is not 
substantiated. 
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Table 2.1. Risk Stratification and Risk-adapted Therapy in ET and PV 
*In the presence of aspirin therapy, the hematocrit target can range between 38% and 
50% and is set at a level that maintain best performance status. 
§Extreme thrombocytosis is defined as a platelet count of >1,000 x 109/L 
||Clinically significant acquired von Willibrand syndrome should be excluded before 
the use of aspirin in patients with extreme thrombocytosis 
¶In hydroxyurea-intolerant or -resistant patients, INF-α (age <60 years) or busulfan 
(age >60 years) might be used (4) 
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Because PV is associated with higher thrombotic risk than ET, the possibility 
that patients who have JAK2V617F may exhibit more severe disease outcome than those 
who did not was examined. In PV, higher JAK2V617F allele burden is correlated with 
more advanced myelofibrosis, greater splenomegaly, and higher white blood cell 
count (48). As compared to those with less than 25% mutant allele, patients harboring 
greater than 75% JAK2V617F allele were at higher relative risk of presenting larger 
spleen or suffering from pruritus. In these patients, the risk of requiring chemotherapy 
or developing major cardiovascular events was significantly increased (49). In 
addition, the presence of JAK2V617F in ET cases is associated with more thrombotic 
complications (12, 50). The presence of JAK2V617F may modify thrombotic risk by 
upregulating P-selectin, thus activating leukocytes and platelets, as well as producing 
dysfunctional RBCs with enhanced adhesiveness (19) Therefore, cytoreductive 
therapy with myelosuppresant quality may positively affect disease progression and 
severity. Several JAK2 inhibitors, such as TG101348 and INCB018424, that reduce 
JAK2V617F allele burden are also being investigated (46).  
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CHAPTER 3 
TWO-PHOTON EXCITED FLUORESCENCE MICROSCOPY 
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Recent advances in non-linear optical imaging methods such as two-photon 
excited fluorescence microscopy (2PEF) have enabled immense progress to be made 
in studies of biological systems as complex as the brain (1). 2PEF has enabled studies 
that visualize subcellular structures and functions, and observe dynamics of specific 
cells in vivo (1, 2). 2PEF provides a means to observe subcellular structures smaller 
than 1 µm and as deep as 1 mm inside the brain without causing damage to the 
surrounding tissue (3, 4) (Fig. 3.1). When combined with chronic surgical 
preparations, structures of interest can be monitored over months. In this chapter, we 
provide a framework of 2PEF by briefly reviewing fluorescence optical imaging, two-
photon excitation and second harmonic generation processes, and describing the 2PEF 
microscope setup. The imaging techniques described in this dissertation were utilized 
in all of our studies presented in Chapters 4 - 7.   
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Figure 3.1. Applications Showing Various Capabilities of Multi-Photon 
Microscopy 
(a) Simultaneous imaging of three different fluorophores in RBL-2H3 cells, 
commonly used as mast cell model in leukemia research, labeled with 4',6-diamidino-
2-phenylindole (DAPI) (DNA, blue pseudo color), PATMAN (plasma membrane, 
green) and tetramethylrhodamine (mitochondria, red). (e) Blood vessels under a tibial 
growth plate perichondrium in a mouse. Red blood cells appear as shadows within the 
fluorescence-containing blood plasma. (f) The angle of the shadow traces in the 
linescan can be used to calculate blood flow velocity. (i) SHG imaging of collagen in a 
baby rat’s tail tendon. Immature fibril segments scatter backward (green), whereas 
mature fibrils scatter forward (red) (5). 
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FLUORESCENCE OPTICAL IMAGING 
Fluorescence optical imaging utilizes fluorophores to visualize biological 
structures. Fluorophores are compounds that absorb energy, become “excited”—the 
absorbed energy leads to electron transitions from the ground state to higher, excited, 
states—and emit light upon relaxation. They can be introduced inside live animals 
through genetic manipulation or injection of fluorescent dyes to label specific 
structures of interest; they can also be endogenous to some cellular structures. As an 
example of fluorophore use, one of our studies utilized Rhodamine-6G, a lipophilic 
dye with high cell membrane permeability, to label white blood cells and a dextran 
tagged with Texas Red to label blood plasma. This allowed us to visualize the cortical 
vasculature and the circulation of leukocytes in blood vessels.  
 
In order to excite a fluorophore, a quantized amount of energy must be 
introduced to enable electrons to transition from the ground energy state to a higher 
excitation state. This energy can be delivered by one photon of the correct energy, or 
multiple photons whose energies add up to the correct amount for that particular kind 
of fluorophore. The energy of a photon is inversely proportional to its wavelength and 
can be described with the following equation: 
! =   ℎ!!  
where h  is Planck’s constant and c and λ are the speed and wavelength of light in 
vacuum, respectively.  
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The amount of energy required to excite a fluorophore depends on the 
chemical structure of that particular fluorophore compound. Once excited, the 
electrons relax to the ground state and emit photons that have less energy than what 
was absorbed due to heat loss (Fig. 3.2). There is a large selection of fluorophores 
available that use a wide range of excitation energies and exhibit an equally wide 
range in the energy/wavelength of emitted photons (6). Such diversity in fluorophore 
properties, coupled with the use of spectral filters and different excitation 
wavelengths, allow many structures labeled with different dyes to be distinguished.  
 
TWO-PHOTON EXCITATION 
Two photons can provide the same amount of energy as a single photon at half 
their wavelength (Fig. 3.2). For the 2-photon nonlinear absorption process to occur, 
both photons must interact with the fluorophore within about 10-16 s of each other, i.e. 
essentially simultaneously. However, the probability that two photons will be 
absorbed simultaneously is quadratically dependent on the light intensity. Therefore, 
high light intensity is required in order for this absorption to occur. In order to avoid 
damaging the biological sample, tightly focused, femtosecond laser pulses are 
exploited to achieve a sufficiently high intensity with low average power (7). This 
technique also leads to a high signal-to-noise ratio. Because two photons must 
simultaneously collide in order to be absorbed by a fluorophore, the only location the 
intensity of the femtosecond pulses are sufficiently high to cause this collision is the 
submicron-sized focal volume. Therefore, scattered excitation light cannot effectively 
generate fluorescence, leading to less background noise (8, 9) (Fig. 3.3).   
34 
 
 
 
 
 
 
 
 
Figure 3.2:  Nonlinear absorption and excitation 
Energy level diagram illustrating the one- and two-photon absorption and excitation 
that enables fluorescence generation, as well as second harmonic generation (10). 
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Figure 3.3:  Localization of Excitation by Two-Photon Excitation 
(a). Single-photon excitation of fluorescein by focused 488-nm light. (b) Two-photon 
excitation using focused femtosecond pulses of 960-nm light (5).  
36 
SECOND HARMONIC GENERATION 
Another process that makes use of nonlinear optical interactions is second 
harmonic generation (SHG). SHG microscopy is appropriate when visualizing 
structures that lack inversion symmetry and are regularly oriented, such as collagen. 
The excitation beam interacts with the nonlinear material, effectively “combining” two 
photons to form a new photon with exactly half the wavelength, emitted in the same 
propagation direction as the input (Fig. 3.2). SHG is dependent on the intensity 
squared of the input pump. Labeling is not required for SHG to occur, but the 
molecules being imaged must lack inversion symmetry. Therefore, this method is 
widely used to study structures that are composed of collagen fibers such as corneal 
tissue and extracellular matrix, or to look at myosin fibers (which also lack inversion 
symmetry) in muscle tissue. We employed this technique to study the rearrangement 
of collagen fibers in engineered tissue, described in Chapter 7. 
 
TWO-PHOTON EXCITED FLUORESCENCE MICROSCOPE SETUP 
Pulse Laser Source 
Titanium-sapphire (Ti:S) lasers are the most widely used in two-photon 
microscopy. Their repetition rate is ~100 MHz, which matches typical fluorescence 
lifetimes of ~10 ns, resulting in minimum saturation and maximized excitation 
efficiency. The wavelength can be tuned over a large range (670-1070 nm) to excite 
many different kinds of fluorophores. In addition, the laser power is variable, 
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depending on the power of the pump laser and design of the Ti:S laser cavity. For 
instance, an 18 W pump is able to produce approximately 3.5 W at 800 nm. 
Excitation Pathway 
Starting from the laser, the beam is routed through a telescope(s) to adjust the 
beam size to ultimately overfill the back aperture of the objective. Because the beam 
intensity profile is Gaussian-shaped, overfilling of the back aperture provides a 
compromise between maximized power transmission and optimal resolution. When 
the laser’s ultrashort pulses propagate through optical elements in the microscope, 
dispersion occurs because longer-wavelength components (e.g. red) travel faster 
through materials than shorter-wavelength components (e.g. blue). In order to 
compensate for this dispersion, a prism is inserted to spatially separate the different-
wavelength components, which are then forced to travel through different path lengths 
before being recombined. One way to implement this dispersion compensation is to 
place a pair of prisms at a point in the system where the laser beam propagates through 
twice.(11) Lastly, the beam intensity at the sample can be controlled using neutral-
density (ND) filters or a rotatable waveplate combined with a polarizer.  
Beam Scanner 
 An image from a 2PEF microscope is acquired by detecting fluorescence 
signals emitted as the laser raster scans over the region of interest. Because 
fluorescence is produced only in a small focal volume, the focal volume is scanned 
through the sample, causing fluorescence. The intensity measurement at each focus 
location becomes a voxel in the final image. Two rotating mirrors are used for XY 
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scanning over the sample. The field of view depends on how far the mirrors can rotate, 
while the acquisition rate depends on how fast the mirrors can move. Thus, there is a 
trade-off between spatial and temporal resolution. The sample or the objective is 
moved to adjust the imaging plane and acquire stacks of 2D images.  
Detectors 
The photons from sample fluorescence are emitted in all directions, but only 
the ones that travel back towards the microscope objective are collected. These 
photons reflect from a dichroic mirror that separates excitation from emission light 
based on their wavelength. The signal passes through a filter for the particular 
wavelength range being detected before reaching a photomultiplier tube, where it is 
then converted into a voltage measurement. This voltage signal is then digitized and 
recorded using software such as MPScope (12) or ScanImage (13) (Fig. 3.4). 
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Figure 3.4:  Components of a Multiphoton Microscope 
(a) Pulse train from a laser mode-locked Ti:S at 80 MHz. (b) Pulses out of the laser 
typically have a full-width half-maximum (FWHM) duration of 100 fs and a spectral 
FWHM (c) of ~10 nm. (d) Schematic of a multi-photon microscopy system. 
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CHAPTER 4 
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ABSTRACT 
Subtle alterations in cerebral blood flow can impact the health and function of 
brain cells and are linked to cognitive decline and dementia. To understand 
hemodynamics in the three-dimensional vascular network of the cerebral cortex, we 
applied two-photon excited fluorescence microscopy to measure the motion of red 
blood cells (RBCs) in individual microvessels throughout the vascular hierarchy in 
anesthetized mice. To resolve heartbeat- and respiration-dependent flow dynamics we 
simultaneously recorded the electrocardiogram and respiratory waveform. We found 
that centerline RBC speed decreased with decreasing vessel diameter in arterioles, 
slowed further through the capillary bed, then increased with increasing vessel 
diameter in venules. RBC flow was pulsatile in nearly all cortical vessels, including 
capillaries and venules. Heartbeat-induced speed modulation decreased through the 
vascular network, while the delay between heartbeat and the time of maximum speed 
increased. Capillary tube hematocrit was 0.21 and did not vary with centerline RBC 
speed or topological position. Spatial RBC flow profiles in surface vessels were 
blunted compared to a parabola, and could be measured at vascular junctions. Finally, 
we observed a transient decrease in RBC speed in surface vessels prior to inspiration. 
In conclusion, we have developed an approach to study detailed characteristics of 
RBC flow in the three-dimensional cortical vasculature, including quantification of 
fluctuations in centerline RBC speed due to cardiac and respiratory rhythms and flow 
profile measurements. These methods and the quantitative data on basal cerebral 
hemodynamics open the door to studies of normal and disease state cerebral 
microcirculation.
44 
INTRODUCTION 
The complex, three-dimensional vascular architecture of the brain presents a 
challenge to studies of microvascular hemodynamics. Larger arterioles form a net at 
the cortical surface and give rise to penetrating arterioles that plunge into the brain and 
feed capillary networks, where most nutrient and metabolite exchange occurs (1). 
These capillaries coalesce into ascending venules, which return to the cortical surface 
and drain into larger surface venules (2). Several lines of evidence suggest that even 
small changes in hemodynamics in the brain can have detrimental impacts on the 
health and function of neurons. Chronic diseases that alter microcirculation, such as 
hypertension (3) and diabetes (4), are risk factors for dementia and are linked to 
cognitive decline (5). Flow disruptions from hyperviscous blood in diseases such as 
polycythemia vera and essential thrombocythemia are linked to neural degeneration 
(6). In addition, occlusion of cerebral microvessels may cause the small, clinically 
silent, strokes that have been associated with cognitive impairment and are a risk 
factor for dementia (7). Furthermore, decreases in the pulsatility of blood flow results 
in higher systemic vascular resistance, decreased oxygen metabolism, and reduced 
efficiency of the microcirculation (8). Novel methods that enable quantification of 
blood flow and vascular changes at the level of individual microvessels in the complex 
cortical vasculature would greatly improve our understanding of the causes and 
consequences of such microvascular pathologies as well as provide insight into 
normal-state hemodynamic regulation. 
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 The most extensive data on blood flow dynamics in microvascular networks 
come from two-dimensional vascular beds, such as the cremaster muscle, omentum, 
and the mesentery, where experimental techniques such as widefield intravital 
microscopy can be readily applied. In these systems, studies of average blood flow 
speed in individual microvessels (9), the distribution of red blood cells (RBCs) at 
microvascular junctions (10), as well as flow pulsatility in capillaries (9) have been 
made. These data have fueled detailed modeling of blood flow dynamics in 
microcirculatory networks that has elucidated the biophysical and physiological 
principles that govern flow (11-14). 
 
 In early studies of brain microcirculation, the average flow speed and 
pulsatility of flow in cortical surface vessels was characterized (15), and more recent 
work has measured flow profiles in pial arterioles using Doppler optical coherence 
tomography (16). However, because of the three-dimensional vascular architecture of 
the brain, techniques with the ability to resolve flow in microvessels at different 
depths in the tissue are required to quantify flow dynamics throughout the vascular 
hierarchy. Recently, two-photon excited fluorescence (2PEF) microscopy has emerged 
as an approach to quantify flow changes in individual cortical microvessels in 
response to neural activity (17) and microvascular occlusion (18-20), with the 
potential to access vessels throughout the full cortical thickness of a mouse (21). 
However, the careful quantification of blood flow dynamics that has been done in two-
dimensional microvascular beds has not yet been performed in brain vascular network. 
For example, previous work has not mapped average flow speed nor heartbeat-induced 
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flow modulation in vessels throughout the cortical network, measured spatial flow 
profiles in brain microvessels, or quantified important hemodynamic parameters such 
as pulse wave velocity. 
 
 Our work aims to overcome the challenges of quantifying blood flow dynamics 
in three-dimensional microvascular networks in live animal models. We coupled 
electrocardiogram (EKG) and respiratory waveform measurements with 2PEF-based 
assessment of RBC speed in individual vessels in anesthetized mice. We quantified 
average centerline RBC flow speed as well as temporal flow fluctuations due to 
cardiac and respiratory rhythms in cortical arterioles, capillaries, and venules. 
Interestingly, we found pulsatile RBC flow in vessels throughout the cortical network, 
including capillaries and venules, and identified respiration-dependent changes in 
cortical blood flow. We quantified the tube hematocrit in brain capillaries and found 
no dependence on centerline RBC speed or position in the vascular hierarchy. We also 
measured time- and space-dependent RBC flow profiles in arterioles, venules, and at 
vascular junctions, and found that spatial flow profiles were blunted in most vessels. 
These data provide a detailed quantification of cerebral hemodynamics in brain 
microvessels, while the methods we developed open the door to future studies of 
alterations in brain hemodynamics due to cerebrovascular disease.   
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MATERIALS AND METHODS 
Animals and surgical preparation  
We used 19 male and three female adult (3-7 month-old), wild-type C57BL/6 
mice, 18-31 g in mass, in this study. Animals were anesthetized with 5% isoflurane in 
oxygen and maintained at 1.5-2% during surgery and imaging. Glycopyrrolate (0.05 
mg per 100-g mouse) was intramuscularly injected to facilitate respiration. 
Bupivacaine (0.1 mL, 0.125%) was subcutaneously administered at the incision site to 
provide local anesthesia. A 5-mm craniotomy was prepared over the parietal cortex. 
An 8-mm diameter, No. 1.5 glass cover slip (50201; World Precision Instruments) was 
glued to the skull using cyanoacrylate (Loctite) and dental cement (Co-Oral-Ite Dental 
Mfg Co.). The space between the exposed brain and the cover glass was filled with 
artificial cerebrospinal fluid (22). Mouse body temperature was maintained at 37.5° C 
with a feedback controlled heating blanket (50-7053P; Harvard Apparatus). Subjects 
received 5% (w/v) glucose in physiological saline (0.5 mL per 100-g mouse) hourly. 
To fluorescently label the vasculature, 0.1 mL of a 2.5% (w/v) solution of 70-kDa 
Texas Red-dextran (D1830; Invitrogen) or 70-kDa fluorescein-conjugated dextran 
(FD70S; Sigma) in physiological saline was injected retroorbitally. The resulting 
dextran concentration in the blood was about 0.0015 g/mL, well below the 
concentration required to trigger RBC aggregation (23). No RBC aggregation was 
observed in our experiments. The care and experimental manipulation of our animals 
have been reviewed and approved by the Institutional Animal Care and Use 
Committee at Cornell University. 
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In vivo two-photon excited fluorescence imaging of cerebral blood vessels  
Images were obtained using a custom-built 2PEF microscope that utilized a 
train of 1040-nm, 1-MHz, 300-fs pulses from a Yb-fiber chirped pulse amplifier 
(FCPA µJewel D-400; IMRA America, Inc.) for two-photon excitation of Texas Red 
or a train of 800-nm, 87-MHz, 100-fs pulses from a Ti:sapphire laser oscillator (MIRA 
HP, pumped by a Verdi-V18; Coherent, Inc.) for fluorescein. The laser pulses were 
scanned in a raster pattern by galvanometric mirrors that are imaged to the back 
aperture of the objective. The two-photon excited fluorescence is reflected by a 
dichroic mirror and relayed to a photomultiplier tube through a filter centered at 645 
or 517 nm, both with 65-nm bandwidth, for Texas Red and fluorescein imaging, 
respectively. Laser scanning and data acquisition was controlled by MPScope software 
(24). Low magnification images of the vasculature in the entire cranial window were 
taken using a 0.28 numerical aperture (NA) 4X air objective (Olympus) (Fig. 4.1A). 
For high-resolution imaging (Fig. 4.1B), RBC flow speed measurements (Fig. 4.1E 
and 1F), and vessel diameter measurements (Fig. 4.1C and 1D), we used a 0.95-NA, 
20X water immersion objective (Olympus). 
 
 To map vascular topology and determine vessel classes (i.e. arteriole vs. 
capillary vs. venule), stacks of images spaced 1 µm axially through the top 350 µm of 
the cortex were obtained (Fig. 4.1B). Penetrating arterioles were identified as vessels 
that branched from readily-identifiable surface arterioles and plunged vertically into 
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the brain. We confirmed the flow was into the brain using line-scan measurements 
(see below). Similarly, ascending venules had flow that emerged from the brain and 
drained into readily-identifiable surface venules. We classed all sub-surface vessels 
branching from penetrating arterioles and ascending venules as capillaries, and 
determined the number of capillary segments separating each capillary from the 
topologically nearest penetrating arteriole or ascending venule. The depth of each 
capillary was measured relative to the middle of the cortical surface vessels. We 
measured blood flow speed and diameter of surface vessels and capillaries up to ten 
branches downstream and upstream from penetrating and ascending vessels, 
respectively. To determine vessel diameter, we recorded images of individual vessels 
stepping from above to below the vessel. These images were averaged, and diameters 
were calculated by manually selecting a portion of the vessel, calculating the area 
above threshold (20% of maximum intensity), and divided this by the length of the 
selected segment.  
 
2PEF measurement of RBC flow speed  
The intravenously-injected dye labels only the blood plasma, so RBCs appear 
as moving dark patches within the vessel lumen. Tracking the motion of these dark 
patches enables measurement of centerline RBC flow speed. We tracked RBC motion 
by repetitively scanning a line along the central axis of single vessels at a line rate of 
1.7 kHz for at least 30 s (17, 20). The space-time image produced by the line-scan 
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contained diagonal dark streaks formed by moving RBCs, with a slope that is 
inversely proportional to the centerline RBC speed (Fig. 4.1E and 1F).  
 
Determination of RBC flow speed from line-scan images  
 To quantify RBC speed in individual vessels from the space-time images, we 
used a Radon transform-based algorithm similar to that of Drew et al. (25). Low 
spatial frequency components in the line-scan image were filtered with a high-pass 
isotropic Gaussian filter. The frequency response of the filter was one minus a scaled 
Gaussian, centered at zero frequency, with a diagonal covariance matrix with values of 
25 pixel-2, and the scaling set so the frequency response at zero frequency is zero. 
Eliminating low-frequency components, such as vertical streaks in the space-time 
image that arise from stationary artifacts in the blood vessel, greatly decreased the 
amount of noise and accentuated the difference between the dark and light streaks 
formed by moving RBCs.  
                              [1] 
 
We then performed a Radon transform on the filtered data, which computes line 
integrals of a two-dimensional function g(x,y) at different angles, θ, from 0 to π with 
respect to the y-axis and at different radial offsets from the origin, ρ, to yield a new 
function g(ρ, θ). When θ = θ* matches the angle of the streaks in a line-scan image, 
the fluctuations of g(ρ,θ*) with respect to ρ are greatest. To identify θ*, we found the 
value of θ where the variance along the ρ-axis was a maximum. The RBC speed is 
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then equal to tan-1θ* multiplied by time and length coefficients that depend on the 
line-scan rate and the spatial extent of the line-scan image. For vessels on the brain 
surface, the image plane was aligned with the plane of the vessel. For sub-surface 
capillaries, there was sometimes a small angle between the image plane and the vessel. 
These angles were measured from the 3D image stacks for each capillary, and the 
calculated centerline RBC flow speed was divided by the cosine of this angle. 
 
Alignment of flow speed measurements to the cardiac cycle  
To measure the temporal centerline RBC flow profile during a cardiac cycle, 
we placed intramuscular leads in the animal’s left anterior and right posterior limbs. 
The EKG signal was amplified (ISO-80 Bio-Amplifier; World Precision Instruments, 
Inc.) and recorded (3.4-kHz sampling rate) simultaneously with the line-scan data 
(Fig. 4.1G). The temporal locations of R-waves (identified by thresholding) in the 
EKG signal were used as markers to align centerline RBC speed measurements from 
each cardiac cycle. A moving average of the RBC flow speed over the cardiac cycle 
was computed with a window size of approximately 1.5% of the cardiac cycle (Fig. 
4.1H). The modulation depth of the flow speed was calculated by normalizing the 
difference between the maximum and minimum flow speed across the cardiac cycle 
by the average flow speed. A vessel was designated as having no flow modulation if 
the difference between maximum and minimum centerline RBC flow speed was less 
than the standard deviation of the speed across the cardiac cycle. The delay between 
heartbeat (R-wave) and the time of maximal flow speed for vessels with flow 
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modulation was calculated and normalized by the average time between heartbeats. 
This delay was aggregated across multiple vessels and animals by temporally aligning 
all measurements using the R-wave of the EKG. 
 
Estimation of capillary tube hematocrit 
Tube hematocrit, hcttube, was calculated from (26) 
                                                          [2] 
where f, v, and R are RBC flux, centerline RBC speed, and vessel radius, respectively. 
RBC flux was extracted from line-scan data by manually counting the number of cells 
in ten 0.3-s time segments, spaced by 3 s throughout the measurement. We only 
included vessels with single file RBC motion, where each RBC made a distinct streak 
in the space-time image. This excluded all capillaries with RBC flux above 270 
RBCs/s, where manual counting of RBC flux was unreliable. We took the mean 
corpuscular volume of mouse RBCs, VRBC, to be 45 µm3 (27). 
 
Spatial blood flow profile measurement  
To obtain a spatial RBC flow profile in individual surface vessels, line-scans 
were sequentially recorded as a function of lateral position, from one vessel wall to the 
other with a step size of 2-4 µm, all in a horizontal plane located at the depth where 
the vessel was widest. The blood flow speed data from all line-scan measurements was 
temporally aligned using the EKG to obtain time- and space-dependent flow profiles 
hcttube =
fVRBC
v!R2
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in individual vessels (Fig. 4.5). The data was smoothed first temporally and then 
spatially using moving averages with a temporal width of ~1.5% of the cardiac cycle 
and a spatial extent of three adjacent line-scans, respectively. For each vessel, the 
spatial flow speed profile, v(r), was fit using the equation (28), 
  [3]
 
where R is the vessel radius, k represents the degree of blunting (a value of two 
corresponds to a parabolic profile), and vmax is the maximum flow speed. Similar 
measurements were made before, at, and after bifurcations or mergers in surface 
arterioles and venules, respectively (Fig. 4.5). In arteriole (venule) measurements, the 
RBC speed profile in the upstream vessel(s) was characterized about one vessel 
diameter upstream from the bifurcation (merger), while downstream branch(es) were 
characterized immediately after the bifurcation (merger).  
 
Alignment of flow speed measurements to the respiratory cycle 
To measure the temporal RBC flow speed profile during each respiratory 
cycle, a breathing signal was recorded simultaneously with EKG and line-scan data 
using a locally-designed breathing sensor. Briefly, an 805-nm light-emitting device 
(LED) illuminated the back of the mouse above the chest cavity from a distance of 
approximately 1 cm. The amplitude of the LED emission was sinusoidally modulated 
at 2 kHz. A photodiode located adjacent to the LED detected the light reflected from 
the animal. The photodiode signal was amplified using a lock-in amplifier (SR530; 
v r( ) = vmax 1!
r
R
k"
#
$$
%
&
''
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Stanford Research Systems) with a 30-ms time constant using the 2-kHz LED 
modulation as a reference. As the animal inhales and exhales, the amount of light 
reaching the photodiode changes slightly, allowing continuous monitoring of the 
breathing waveform (Fig. 4.7A, top). Line-scan data were recorded concurrently with 
both EKG and breath signals for 10 minutes. To align RBC flow speed data with the 
respiratory cycle, we used the same method described for cardiac cycle alignment, but 
using the inspiration signal as the alignment marker (Fig. 4.7B). To align flow speed 
data with both the cardiac and respiratory waveforms, we used R-waves of the EKG 
signal and inspiration peaks of the respiratory signal as markers and binned each flow 
speed measurement into a two-dimensional matrix that specifies the measurement time 
with respect to both heartbeat and inspiration. The data was then smoothed using a 
rectangular two-dimensional moving average that had a width of 5% of the cardiac 
cycle and a length of 5% of the respiratory cycle. The data was used to create a three-
dimensional plot that decoupled RBC flow speed dependence on heartbeat and 
breathing (Fig. 4.7D and 7E). 
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RESULTS 
Temporal blood flow fluctuations due to rhythmic cardiac contractions  
We used 2PEF imaging of fluorescently-labeled vasculature in craniotomized, 
anesthetized mice to quantify the temporal blood flow dynamics in cortical 
microvessels. Vascular topology was traced in three-dimensional image stacks to 
identify surface and penetrating arterioles, capillaries, and ascending and surface 
venules (Fig. 4.1A and 1B). We measured diameter and centerline RBC flow speed 
(by tracking RBC motion) in individual arterioles (Fig. 4.1C and 1E), capillaries (Fig. 
4.1D and 1F), and venules. RBC speed measurements in each vessel were temporally 
aligned to heartbeat (Fig. 4.1H). The average cardiac period was 0.14±0.04 s (mean ± 
standard deviation), which corresponds to a heart rate of 430±100 bpm (20 mice). 
Arteriole temporal centerline RBC flow profiles typically displayed a clear speed 
modulation with heartbeat (Fig. 4.1Hi), while capillaries (Fig. 4.1Hii) and venules 
(Fig. 4.1Hiv) showed smaller modulation depth, with speed modulation not detectable 
above noise in some capillaries (Fig. 4.1Hiii) and venules. The delay between the 
heartbeat and the time of maximum centerline RBC flow speed was shortest in 
arterioles, followed by capillaries, then venules (Fig. 4.1H). 
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Fig. 4.1. In vivo 2PEF imaging of vascular topology and cerebral blood flow 
during the cardiac cycle. (A) Low magnification 2PEF image of fluorescently-
labeled brain vasculature in an anesthetized mouse. (B) Three-dimensional rendering 
of the vasculature with the brain surface at the top of the image. Axially-projected 
image of an arteriole (C) and a capillary (D) with their line-scan images (E and F). The 
arrow in (E) indicates RBC flow speed increase due to a heartbeat. (G) EKG used to 
align the flow speed data. (H) Centerline RBC speed of an arteriole (i), two capillaries 
(ii and iii), and a venule (iv) as a function time, expressed as a fraction of the cardiac 
cycle. The colors of the vessel labels in H correspond to the colored highlights in the 
2PEF images and line-scan images. 
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Quantification of average RBC flow speed and heartbeat-dependent speed 
fluctuations 
We measured temporal RBC speed profiles in microvessels throughout the 
cortical vascular hierarchy. Centerline RBC flow speed (averaged over ~200 cardiac 
cycles) significantly decreased (from 13 to 3 mm/s) with decreasing diameter (60 to 10 
µm) in surface and penetrating arterioles (p < 0.0003, Cuzick’s trend test (29), 66 
vessels, 14 animals) (Fig. 4.2A). Capillaries (<10-µm diameter) exhibited the slowest 
RBC flow speeds of 1.5±1.2 mm/s (156 vessels, 17 animals), with capillaries 
topologically closer to arterioles having significantly higher flow speeds than those 
closer to venules (p < 0.0001, Cuzick’s trend test, Fig. 4.2D). We found no 
dependence of capillary blood flow speed on the depth of the vessel beneath the 
cortical surface (Fig. 4.3). Flow speed significantly increased (1 to 4 mm/s) with 
increasing vessel diameter (10 to 60 µm) in ascending and surface venules (p < 
0.0001, Cuzick’s trend test, 56 vessels, 14 animals), but remained slow compared to 
arterioles (p < 0.0001, two-sided t-test, Fig. 4.2A). The average magnitude of the 
centerline RBC flow speed modulation with heartbeat decreased continuously from 
arterioles (43±15%, 61 vessels) to capillaries (28±12%, 81 vessels) to venules 
(10±8%, 54 vessels) (p < 0.0001, ANOVA, Fig. 4.2B and 2E). The flow modulation 
was undetectable in many of the slower vessels (Fig. 4.2B, inset), especially in 
capillaries topologically further from penetrating arterioles (Fig. 4.2E, inset). Nearly 
all venules exhibited some modulation in blood flow speed with heartbeat. The delay 
between heartbeat and the time of maximum RBC flow speed significantly increased 
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for vessels topologically further away from the heart (p < 0.0001, Cuzick’s trend test, 
Fig. 4.2C and 2F)   
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Fig. 4.2. Average centerline RBC speed, flow speed modulation, and delay to 
maximal flow speed for cerebral microvessels. (A) Average centerline RBC speed, 
(B) flow speed modulation with heartbeat, and (C) delay between heartbeat and time 
of maximal flow speed as a function of vessel diameter. To display the progression of 
blood flow through the vascular network, data for arterioles (venules) are displayed on 
the left (right) portion of the plot with decreasing (increasing) diameter. Capillaries are 
toward the middle and placed to the arteriole or venule side based on which they are 
topologically closer to. (D) Average centerline RBC speed, (E) flow speed modulation 
with heartbeat, and (F) delay between heartbeat and time of maximal flow speed for 
capillaries as a function of topological connectivity to penetrating arterioles (PA) from 
the left side and to ascending venules (AV) from the right side. 
  
60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.3. Capillary RBC flow speed as a function of depth beneath the cortical 
surface.  
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Capillary tube hematocrit 
We manually counted RBC flux in the line-scan data and determined the tube 
hematocrit of many of the capillaries using Eq. 2. We found that the average capillary 
hematocrit was 0.22±0.19 (n = 97 capillaries), with a weak tendency for hematocrit to 
increase for smaller diameter vessels (p = 0.0005, Cuzick’s trend test, Fig. 4.4A), 
where RBCs deform significantly as they squeeze through the capillary and thus 
occupy a larger volume fraction. Tube hematocrit did not depend on the mean 
centerline flow speed in the capillary over the narrow range of flow speeds 
investigated (26) (Fig. 4.4B) or on the topological position of the capillary in the 
vascular bed (Fig. 4.4C). 
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Fig. 4.4. Capillary tube hematocrit in the cortical microvascular network. Tube 
hematocrit as a function of (A) capillary diameter, (B) centerline RBC speed, and (C) 
topological connectivity to penetrating arterioles (PA) from the left side and to 
ascending venules (AV) from the right side. 
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Spatial blood flow profiles during a cardiac cycle  
Spatial RBC flow profiles were obtained in vessels by measuring RBC flow 
speed at different positions within the vessel lumen. In both arterioles (Fig. 4.5B) and 
venules (Fig. 4.5C), flow speed was fastest in the center of the vessel and decreased 
toward the vessel walls. In both vessel classes, the spatial RBC flow profile was 
slightly blunted (average blunting index, k, of 3.3±1.1 in arterioles; k = 3.7±1.5 in 
venules) as compared to the parabolic flow profile expected for steady laminar flow 
(Fig. 4.5Biii and 5Ciii). In arterioles, the degree of blunting was significantly higher at 
diastole (k = 3.4±1.1) as compared to systole (k = 3.1±1.1; p = 0.002, paired t-test). 
Vessels with slower flow speeds tended toward increased blunting regardless of vessel 
class or cardiac phase (Fig. 4.5D). 
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Fig. 4.5. RBC flow speed across the spatial profile of an arteriole and venule over 
the cardiac cycle. (A) Low magnification 2PEF image of fluorescently-labeled brain 
vasculature. RBC speed from wall-to-wall across a surface arteriole (Bi) and a surface 
venule (Ci) over the cardiac cycle with corresponding 2PEF images of the vessels (Bii 
and Cii). The spatial flow speed profiles during systole and diastole are also displayed 
(Biii and Ciii). (D) Blunting index, k, of surface arterioles and venules as a function of 
maximum RBC flow speed during systole and diastole, determined from fits of the 
flow profile at systole and diastole to Eq. 3. 
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 We measured spatial RBC flow speed profiles upstream from, at, and 
downstream from surface arteriole bifurcations (Fig. 4.6A) and surface venule 
mergers (Fig. 4.6C). At the arteriole bifurcation, a spatial flow profile with two peaks 
was observed, while the peaks in the downstream branches were shifted laterally 
toward the outer sides of the vessels (Fig. 4.6B). Similarly, at the venule merger, a 
double-peaked flow profile was observed (Fig. 4.6D). We found that RBC flux 
(calculated assuming an axially symmetric flow profile) was conserved to within 30% 
and 11% in the arteriole and venule junctions, respectively. These errors likely reflect 
the fact that there was some physiological drift during the approximately one-hour 
time required to take all the necessary line-scan measurements and that the 
downstream flow profiles this close to a junction are likely not fully axially 
symmetric. Because our approach for measuring flow speed relies on tracking RBC 
motion, the flow profiles in Figs. 5 and 6 are effectively spatially-averaged over the 
~7-µm size of an RBC. This averaging likely reduces the depth of the dip in flow 
speed observed at the center of the flow profile in the bifurcation and merger shown in 
Fig. 4.6B and D, respectively. 
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Fig. 4.6. Spatial RBC flow profiles upstream, at, and downstream of vascular 
junctions. (A) 2PEF image of an arteriole bifurcation. (B) Wall-to-wall flow profiles 
in the upstream arteriole, at the bifurcation, and in the downstream branches during 
systole and diastole. (C) 2PEF image of a venule merger and (D) corresponding flow 
profiles.  
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Temporal blood flow fluctuations due to breathing  
In two animals, we measured centerline RBC flow speed in surface arterioles 
and venules while monitoring both respiration and heartbeat (Fig. 4.7A), and then 
aligned the flow speed data with respect to both respiratory (Fig. 4.7B) and cardiac 
(Fig. 4.7C) cycles. In arterioles (Fig. 4.7D) and venules (Fig. 4.7E), we observed a 
33±5% (3 vessels, 2 animals) and 29±15% (3 vessels, 2 animals) decrease in blood 
flow speed just before inhalation (defined by chest wall motion), respectively (Fig. 
4.7F). This flow speed decrease was preserved at all phases of the cardiac cycle, and 
occurred significantly earlier in arterioles (0.08±0.004 of a breath period before 
inhalation) than in venules (0.05±0.012; p = 0.004, two-tailed t-test; Fig. 4.7G). To 
rule out motion artifact as a source of this observation, we measured RBC flow speed 
at locations shifted by ~10 µm horizontally and vertically from the center axis of an 
arteriole and found a similar decrease in flow speed just prior to inspiration at all 
locations (Fig. 4.8). 
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Fig. 4.7. Centerline RBC flow speed dependence on respiration and heartbeat. 
(A) Simultaneously recorded respiratory waveform and EKG. Centerline RBC flow 
speed in an arteriole aligned relative to respiratory (B) and cardiac (C) cycles. Two-
dimensional plot of RBC flow speed in an arteriole (D) and a venule (E) as a function 
of both respiratory and cardiac cycle. Boxplot of flow speed modulation due to 
breathing (F) and delay from the time of the respiration-dependent decrease in flow 
speed to inspiration (G) in surface arterioles and venules. 
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Fig. 4.8. Respiration-dependent flow speed fluctuations at different positions 
inside the lumen of a 43-µm diameter cortical arteriole. Each flow speed 
measurement was displaced approximately 10 µm from the vessel center in the 
direction indicated by the schematic at center of the figure. 
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DISCUSSION 
Average RBC flow speed in cerebral vessels  
We quantified centerline RBC flow speed in vessels throughout the cortical 
vascular hierarchy, starting from surface and penetrating arterioles, continuing to 
capillaries within the three-dimensional network deep in the cortex, and finally to 
ascending and surface venules. As expected, centerline RBC flow speed decreased 
with decreasing vessel diameter in arterioles, further slowed in capillaries, then 
increased slightly with increasing vessel diameter in venules (Fig. 4.2A). In 
capillaries, flow speeds decreased about three-fold over the first five capillary 
branches downstream from penetrating arterioles, then remained relatively uniform, at 
about 1 mm/s, through the rest of the capillary bed (Fig. 4.2D), with no dependence on 
depth beneath the cortical surface (Fig. 4.3). The average flow speeds for different 
class vessels measured here agree well with previous measurements of cerebral blood 
flow in rodents for arterioles (19, 20), capillaries (17), and venules (15, 30).  
 
Pulsatile flow due to heartbeat  
Pulsatile RBC flow was observed in all classes of cortical microvessels, 
including capillaries and venules, with a decreasing modulation depth from arterioles 
to capillaries to venules (Fig. 4.2B). In the majority of vessels of all classes, flow 
speed was modulated by heartbeat, although some of the slower capillaries and 
venules did not clearly show modulation. However, the variability in RBC speed was 
proportionally larger in these slower vessels, reducing our ability to resolve heartbeat-
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induced speed changes. As a result, the decrease in the number of vessels showing 
modulation with decreasing average flow speed may be due, in part, to this decreased 
sensitivity. Our data thus establishes the minimum fraction of vessels whose flow 
speed is modulated by heartbeat. In previous work, heartbeat-induced speed 
modulation has been quantified in the aorta (31) and in large arteries (32) and veins 
(33) in the thoracic cavity of larger animals such as pigs and dogs. Pulsatile flow has 
also been observed in surface arterioles and venules in the brain of rodents (15) and in 
two-dimensional microvascular beds such as omentum and mesentery (34). Due to 
limitations in the spatial and temporal resolution as well as flow speed measurement 
precision of previous approaches, the pulsatility of blood flow in cortical venules and 
microvessels less than 10-µm diameter was not observed until now. The magnitude of 
the heartbeat-induced speed modulation decreased in more distal vessels, consistent 
with dampening of the pressure pulse from the heartbeat as it travels through the 
distensible vascular network and loses energy to viscous damping (12) (Fig. 4.2B).  
 
 As expected, the interval between ventricular ejection and the time of 
maximum flow speed increased for more distal vessels (Fig. 4.2C and 2F) because the 
pressure wave from the heartbeat must travel through the distensible vascular system 
(35). The interval between the time of maximal flow speed in penetrating arterioles 
and ascending venules was about 0.02 s, on average (Fig. 4.2C). In mouse cortex, the 
shortest capillary path from a penetrating arteriole to an ascending venule has a 
median value of 490 µm (330 - 670 µm interquartile range, private communication 
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from P. Tsai based on data in Ref. (36)). Using these data, we estimate the pulse wave 
velocity through the cortical capillary network to be ~25 mm/s.  
 
 In microvessels, the propagation of the pressure pulse from the heart is 
dominated by viscous forces and is described by a diffusion equation (13, 14) 
                                                       [4] 
where P is the intraluminal pressure as a function of position along the vessel, x, and 
time, t. The viscous resistance term, G, is giving by 
                                                            [5] 
where µ is the viscosity of blood and R is the vessel radius. The vascular compliance, 
C, is described by 
                                                      [6] 
where a is the ratio of vessel radius to vessel wall thickness and E is the Young’s 
modulus of the vessel wall. The solution to Eq. 4 is a strongly damped oscillatory 
wave that propagates with a speed, c, given by 
                                                             [7] 
where ω is the angular frequency of the heartbeat. To determine the blood viscosity, 
we followed the approach of Ref. (37), using a tube hematocrit of 0.22 and vessel 
radius of 2.9 µm (the averages for the capillaries in this study). We found the relative 
viscosity to be 1.2, which yields a whole blood viscosity in the capillary bed of 1.6 X 
d 2P
dx2 =GC
dP
dt
G = 8µ
!R4
C = 3!R
2 (a+1)2
E(2a+1)
c = 2!GC
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10-3 Pa s (38). Using the 25 mm/s pulse wave velocity we estimated experimentally, a 
vessel wall thickness of 0.5 µm (39), and the measured average 7.1-Hz heart rate, Eq. 
7 can be solved for the Young’s modulus of the vessel, giving a value of 0.12 MPa. 
This value for the modulus of brain capillaries is in fair agreement with measurements 
of microvessel modulus from rat spinotrapezius muscle (40), but smaller than previous 
estimates in cat omentum and mesentery (41, 42). 
 
Spatial flow profiles in surface arterioles and venules  
Blood is composed of both cellular components and the liquid blood plasma. 
For arteries and veins, where the vessel diameter is much larger than the size of an 
RBC (6 - 8 µm) (27), whole blood can be approximated as a bulk fluid. For the 
microvessels considered in this study, the size of an RBC is a significant fraction of 
the vessel diameter. This leads to deviations from the parabolic flow profile expected 
for laminar flow of a Newtonian fluid (12), which is governed by Hagen-Poiseuille’s 
Law. In particular, blunting of the flow profile (i.e. exponent greater than two) is 
expected in smaller vessels or in low-flow vessels, where RBCs tend to aggregate 
(12). The degree of blunting we observed in both arterioles (k = 3.3±1.1) and venules 
(k = 3.7±1.5) (Fig. 4.5D) compare well with previous measurements of 2.4 - 4 for 
rabbit mesenteric arterioles (28). For surface arterioles, the blunting of the spatial 
profile is more pronounced during the diastolic phase in both our study (Fig. 4.5D) 
and in previous work (12), likely due to increased RBCs aggregation at lower shear 
rate (28). 
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Diverging and converging flow profiles 
Previous studies have investigated blood flow at bifurcations of large arteries, 
which have fast flow speed and high Reynolds number (43). In microcirculatory 
systems, detailed in vivo measurements of time and space dependent blood flow 
profiles at vessel junctions have not been made for vessels smaller than 2-mm 
diameter. In this study, we resolved the spatial flow profile at bifurcations and mergers 
of cortical surface arterioles and venules, respectively, and observed a double-peaked 
profile at the junction (Fig. 4.6B and 6D). Interestingly, the flow profile of the two 
branches immediately downstream from an arteriole bifurcation displayed flow speed 
maxima that were skewed toward the outer edge of the bifurcation. This asymmetric 
flow profile is consistent with low Reynolds flow that is dominated by viscous forces, 
and is skewed in the opposite direction that is found in bifurcations of larger vessels 
with faster flow speeds, such as the carotid bifurcation (43). After about one vessel 
diameter away from the junction, the spatial flow profiles shifted so the maximum 
speed was once again at the vessel center.  
 
Blood flow speed modulation due to respiration  
Breath inhalation was found to cause a transient decrease in centerline RBC 
flow speed in both cortical arterioles and venules (Fig. 4.7). The effect of breathing on 
blood flow speed has previously been examined in the vena cava, pulmonary artery 
and vein, and aorta in dogs (44, 45) and humans (33). During inspiration, the 
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diaphragm movement creates a negative pressure in the thoracic cavity allowing lung 
expansion, and thus an increase in the total vascular volume of the lung. This causes a 
decrease in pulmonary return to the heart, which leads to a decrease in systemic blood 
pressure (45), although other studies have disagreed (33, 44). The transient flow speed 
decrease we observe in both surface arterioles and venules is consistent with such a 
decrease in systemic blood pressure during inhalation.  
 
Comparison to other cerebral blood flow measurement modalities 
Most current approaches for measuring cerebral hemodynamics focus on 
quantification of regional changes in blood flow and do not resolve flow dynamics in 
individual microvessels. Clinical tools include magnetic resonance imaging (MRI) 
approaches, such as blood oxygen level dependent (BOLD) MRI (46) and arterial spin 
labeling (47), as well as positron emission tomography (46, 48). These techniques are 
well suited to the measurement of regional changes of blood flow in the brain of 
humans and animals models with a spatial resolution of about a millimeter to a 
centimeter (46-48). Laser Doppler spectroscopy (48), intrinsic optical imaging (49), 
and laser speckle contrast imaging (50) enable millimeter or better resolution mapping 
of flow changes in animal models, but still cannot resolve dynamics in individual 
microvessels. Doppler optical coherence tomography has recently emerged as an 
approach to mapping cerebral blood flow in many diving and ascending vessels 
simultaneously, but still cannot resolve flow in individual capillaries (16). 
Transcranial Doppler ultrasonography enables measurement of detailed blood flow 
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information including pulsatile flow due to each heartbeat (48), but is unable to 
resolve blood flow in vessels smaller than the middle cerebral artery. It is optical 
microscopies that provide the necessary spatial and temporal resolution to quantify 
flow dynamics in vessels as small as capillaries. However, standard techniques such as 
confocal microscopy are limited in depth penetration by optical scattering (51). In vivo 
2PEF microscopy overcomes some of these limitations and has allowed in vivo 
imaging of vascular topology and blood flow in murine brain to a depth of 1 mm (21). 
This technique relies on nonlinear excitation of fluorescent molecules by tightly 
focused, infrared wavelength, femtosecond-duration laser pulses to restrict 
fluorescence emission to the focal volume, which is scanned in three-dimensions to 
form an image. With this tool, it is possible to image fluorescently-labeled objects 
with micrometer resolution deep in the brain tissue of live, anesthetized rodents 
without damaging the tissue (52, 53). When the blood plasma is labeled with an 
intravenously-injected fluorescent dye, this imaging method enables in vivo mapping 
of vascular architecture and, by directly tracking the motion of unlabeled RBCs, 
quantification of flow speed in individual vascular segments (17, 20). This flow 
measurement technique, however, is able to quantify only the motion of RBCs, not of 
blood plasma. As a result, we are unable to characterize differences in average speed, 
or in temporal or spatial flow profiles, for blood plasma versus RBCs. 
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CONCLUSIONS  
We have shown that 2PEF microscopy, together with EKG and respiratory 
waveform recordings, enables cerebral blood flow dynamics to be quantified with high 
spatial and temporal resolution and high flow speed precision in individual cerebral 
microvessels. The detailed information on cerebral hemodynamics obtained in this 
study and the experimental approach we developed has many applications. Because 
disruption of blood flow in small cerebral vessels is associated with cognitive decline 
and dementia (5), our measurements of hemodynamics in cortical arterioles, 
capillaries, and venules can serve as a foundation for studies of altered brain blood 
flow in pathological conditions. Our discovery of pulsatile blood flow in brain 
capillaries is also of importance. Loss of pulsatile flow leads to increases in systematic 
vascular resistance and may cause tissue damage (8), while in pulmonary capillaries 
pulsatile blood flow is essential for efficient oxygen transfer (8). Pulsatility may 
similarly be important for brain capillary function and neural tissue health. The 
interval between heartbeat and the time of maximum flow speed is an indicator of 
vascular health. Clinically, increases in pulse wave velocity are used to diagnose 
arterial stiffening (e.g. due to atherosclerosis), which is a contributing factor to 
cognitive decline and dementia (3). In addition, changes in the microcirculation that 
contribute to the central nervous system damage that results from chronic hypertension 
may depend, in part, on the abnormal transmission of highly pulsatile blood pressure 
into the microvascular networks of the brain (and other highly perfused organs with 
low vascular resistance) (5). Our experimental approach allows these important 
hemodynamic phenomena to be investigated in murine brain vasculature. When 
79 
combined with transgenic animals, this approach may allow in-depth studies of the 
role of microvascular dysfunction in a variety of brain diseases, including Alzheimer’s 
disease and vascular dementia. Previous work has found that endothelial cells 
experiencing low shear or turbulent flow become seed sites for the formation of 
atherosclerotic plaques, and that such flow disturbances are common at arterial 
bifurcations (54) . Our method to quantify flow profiles in individual microvessels and 
at microvascular junctions could enable investigation of potentially pathogenic flow in 
these small diameter vessels. The ability to carefully quantify these blood flow 
dynamics, as well investigate how hemodynamics may change in pathological 
conditions, provides a new window on normal and disease-state cerebral 
microcirculation. 
80 
REFERENCES 
 
1. P. Blinder, A. Y. Shih, C. Rafie, D. Kleinfeld, Topological basis for the robust 
distribution of blood to rodent neocortex. Proc Natl Acad Sci USA 107, 12670 
(Jul 13, 2010). 
2. S. Lorthois, F. Cassot, F. Lauwers, Simulation study of brain blood flow 
regulation by intra-cortical arterioles in an anatomically accurate large human 
vascular network: Part I: Methodology and baseline flow. NeuroImage 54, 
1031 (Jan 15, 2011). 
3. G. F. Mitchell et al., Arterial stiffness, pressure and flow pulsatility and brain 
structure and function: the Age, Gene/Environment Susceptibility - Reykjavik 
Study. Brain 134, 3398 (Nov 1, 2011). 
4. K. Cruickshank et al., Aortic pulse-wave velocity and its relationship to 
mortality in diabetes and glucose intolerance: an integrated index of vascular 
function? Circulation 106, 2085 (Oct 15, 2002). 
5. J. O'Brien, Vascular cognitive impairment. Am J Geriatr Psychiatry 14, 724 
(Sep 1, 2006). 
6. K. Heinicke et al., Excessive erythrocytosis in adult mice overexpressing 
erythropoietin leads to hepatic, renal, neuronal, and muscular degeneration. Am 
J Physiol Regul Integr Comp Physiol 291, R947 (Oct 1, 2006). 
7. L. Pantoni, Cerebral small vessel disease: from pathogenesis and clinical 
characteristics to therapeutic challenges. Lancet Neurol 9, 689 (Jul 1, 2010). 
 81 
8. H. Wilkens, W. Regelson, F. S. Hoffmeister, The physiolgic importance of 
pulsatile blood flow. N Engl J Med 267, 443 (Aug 30, 1962). 
9. B. W. Zweifach, H. H. Lipowsky, Quantitative studies of microcirculatory 
structure and function. III. Microvascular hemodynamics of cat mesentery and 
rabbit omentum. Circ Res 41, 380 (Sep 1, 1977). 
10. A. Pries, K. Ley, M. Claassen, P. Gaehtgens, Red cell distribution at 
microvascular bifurcations. Microvasc Res 38, 81 (Jul 1, 1989). 
11. D. Audet, W. Olbricht, The motion of model cells at capillary bifurcations. 
Microvasc Res 33, 377 (May 1, 1987). 
12. A. S. Popel, P. C. Johnson, Microcirculation and Hemorheology. Annual 
review of fluid mechanics 37, 43 (Jan 1, 2005). 
13. J. F. Gross, M. Intaglietta, B. W. Zweifach, Network model of pulsatile 
hemodynamics in the microcirculation of the rabbit omentum. Am J Physiol 
226, 1117 (May 1, 1974). 
14. G. W. Schmid-Schönbein, S. Y. Lee, D. Sutton, Dynamic viscous flow in 
distensible vessels of skeletal muscle microcirculation: application to pressure 
and flow transients. Biorheology 26, 215 (Jan 1, 1989). 
15. W. Rosenblum, Erythrocyte velocity and a velocity pulse in minute blood 
vessels on the surface of the mouse brain. Circ Res 24, 887 (Jun 1, 1969). 
16. V. J. Srinivasan et al., Optical coherence tomography for the quantitative study 
of cerebrovascular physiology. J Cereb Blood Flow Metab,  (Mar 2, 2011). 
17. D. Kleinfeld, P. Mitra, F. Helmchen, W. Denk, Fluctuations and stimulus-
induced changes in blood flow observed in individual capillaries in layers 2 
 82 
through 4 of rat neocortex. Proc Natl Acad Sci U S A 95, 15741 (Dec 22, 
1998). 
18. N. Nishimura, N. L. Rosidi, C. Iadecola, C. B. Schaffer, Limitations of 
collateral flow after occlusion of a single cortical penetrating arteriole. J Cereb 
Blood Flow Metab 30, 1914 (Dec 1, 2010). 
19. N. Nishimura et al., Targeted insult to subsurface cortical blood vessels using 
ultrashort laser pulses: three models of stroke. Nat Methods 3, 99 (Feb 1, 
2006). 
20. C. Schaffer et al., Two-photon imaging of cortical surface microvessels reveals 
a robust redistribution in blood flow after vascular occlusion. PLoS Biol 4, e22 
(Feb 1, 2006). 
21. D. Kobat et al., Deep tissue multiphoton microscopy using longer wavelength 
excitation. Opt Express 17, 13354 (Aug 3, 2009). 
22. D. Kleinfeld, K. R. Delaney, Distributed representation of vibrissa movement 
in the upper layers of somatosensory cortex revealed with voltage-sensitive 
dyes. J Comp Neurol 375, 89 (Nov 4, 1996). 
23. B. Neu, R. Wenby, H. J. Meiselman, Effects of Dextran Molecular Weight on 
Red Blood Cell Aggregation. Biophysical Journal 95, 3059 (Sep 15, 2008). 
24. Q. Nguyen, P. Tsai, D. Kleinfeld, MPScope: a versatile software suite for 
multiphoton microscopy. J Neurosci Methods 156, 351 (Sep 30, 2006). 
25. P. Drew, P. Blinder, G. Cauwenberghs, A. Shih, D. Kleinfeld, Rapid 
determination of particle velocity from space-time images using the Radon 
transform. J Comput Neurosci,  (May 21, 2009). 
 83 
26. A. A. Constantinescu, H. Vink, J. A. Spaan, Elevated capillary tube hematocrit 
reflects degradation of endothelial cell glycocalyx by oxidized LDL. Am J 
Physiol Heart Circ Physiol 280, H1051 (Mar 1, 2001). 
27. C. M. Hawkey, P. M. Bennett, S. C. Gascoyne, M. G. Hart, J. K. Kirkwood, 
Erythrocyte size, number and haemoglobin content in vertebrates. Br J 
Haematol 77, 392 (Mar 1, 1991). 
28. G. Tangelder et al., Velocity profiles of blood platelets and red blood cells 
flowing in arterioles of the rabbit mesentery. Circ Res 59, 505 (Nov 1, 1986). 
29. J. Cuzick, A Wilcoxon-type test for trend. Stat Med 4, 87 (Jan 1, 1985). 
30. J. Nguyen, N. Nishimura, R. N. Fetcho, C. Iadecola, C. B. Schaffer, Occlusion 
of cortical ascending venules causes blood flow decreases, reversals in flow 
direction, and vessel dilation in upstream capillaries. J Cereb Blood Flow 
Metab 31, 2243 (Nov 1, 2011). 
31. W. Seed, N. Wood, Velocity patterns in the aorta. Cardiovasc Res 5, 319 (Jul 
1, 1971). 
32. C. Mills et al., Pressure-flow relationships and vascular impedance in man. 
Cardiovasc Res 4, 405 (Oct 1, 1970). 
33. L. Wexler, D. Bergel, I. Gabe, G. Makin, C. Mills, Velocity of blood flow in 
normal human venae cavae. Circ Res 23, 349 (Sep 1, 1968). 
34. A. G. Salotto, L. F. Muscarella, J. Melbin, J. K. Li, A. Noordergraaf, Pressure 
pulse transmission into vascular beds. Microvasc Res 32, 152 (Sep 1, 1986). 
35. G. Schmid-Schonbein, Biomechanics of microcirculatory blood perfusion. 
Annu Rev Biomed Eng 1, 73 (1999). 
 84 
36. P. Tsai et al., Correlations of neuronal and microvascular densities in murine 
cortex revealed by direct counting and colocalization of nuclei and vessels. J 
Neurosci 29, 14553 (Nov 18, 2009). 
37. A. R. Pries, D. Neuhaus, P. Gaehtgens, Blood viscosity in tube flow: 
dependence on diameter and hematocrit. Am J Physiol 263, H1770 (Dec 1, 
1992). 
38. U. Windberger, A. Bartholovitsch, R. Plasenzotti, K. J. Korak, G. Heinze, 
Whole blood viscosity, plasma viscosity and erythrocyte aggregation in nine 
mammalian species: reference values and comparison of data. Exp Physiol 88, 
431 (May 1, 2003). 
39. A. C. H. Guyton, J E, Textbook of Medical Physiology.  (Saunders, ed. 11, 
2005). 
40. T. C. Skalak, G. W. Schmid-Schonbein, Viscoelastic properties of 
microvessels in rat spinotrapezius muscle. J Biomech Eng 108, 193 (Aug 1, 
1986). 
41. L. H. Smaje, P. A. Fraser, G. Clough, The distensibility of single capillaries 
and venules in the cat mesentery. Microvasc Res 20, 358 (Nov 1, 1980). 
42. M. Intaglietta, D. R. Richardson, W. R. Tompkins, Blood pressure, flow, and 
elastic properties in microvessels of cat omentum. Am J Physiol 221, 922 (Sep 
1, 1971). 
43. M. Motomiya, T. Karino, Flow patterns in the human carotid artery 
bifurcation. Stroke 15, 50 (Jan 1, 1984). 
 85 
44. W. G. Guntheroth, B. C. Morgan, G. L. Mullins, Effect of respiration on 
venous return and stroke volume in cardiac tamponade. Mechanism of pulsus 
parodoxus. Circ Res 20, 381 (Apr 1, 1967). 
45. B. Morgan, D. Dillard, W. Guntheroth, Effect of cardiac and respiratory cycle 
on pulmonary vein flow, pressure, and diameter. J Appl Physiol 21, 1276 (Jul 
1, 1966). 
46. D. P. Bulte et al., Quantitative measurement of cerebral physiology using 
respiratory-calibrated MRI. NeuroImage,  (Dec 22, 2011). 
47. R. B. Buxton, L. R. Frank, A model for the coupling between cerebral blood 
flow and oxygen metabolism during neural stimulation. J Cereb Blood Flow 
Metab 17, 64 (Jan 1, 1997). 
48. W. Heiss, M. Forsting, H. Diener, Imaging in cerebrovascular disease. Curr 
Opin Neurol 14, 67 (Feb 1, 2001). 
49. D. Y. Ts'o, R. D. Frostig, E. E. Lieke, A. GRINVALD, Functional 
organization of primate visual cortex revealed by high resolution optical 
imaging. Science 249, 417 (Jul 27, 1990). 
50. D. A. Boas, A. K. Dunn, Laser speckle contrast imaging in biomedical optics. 
J Biomed Opt 15, 011109 (Jan 1, 2010). 
51. L. Nyman et al., Real-time, multidimensional in vivo imaging used to 
investigate blood flow in mouse pancreatic islets. J Clin Invest 118, 3790 (Nov 
1, 2008). 
52. W. Denk, J. Strickler, W. Webb, Two-photon laser scanning fluorescence 
microscopy. Science 248, 73 (Apr 6, 1990). 
 86 
53. W. Zipfel, R. Williams, W. Webb, Nonlinear magic: multiphoton microscopy 
in the biosciences. Nat Biotechnol 21, 1369 (Nov 1, 2003). 
54. C. Hahn, M. A. Schwartz, The role of cellular adaptation to mechanical forces 
in atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 28, 
2101 (Dec 1, 2008). 
 
 
87 
CHAPTER 5 
IN VIVO TWO-PHOTON IMAGING OF CEREBRAL MICROCIRCULATION IN 
ANIMAL MODELS OF ESSENTIAL THROMBOCYTHEMIA AND 
POLYCYTHEMIA VERA: PLATELET AND LEUKOCYTE CONTRIBUTIONS 
TO CORTICAL MICROVASCULAR DYSFUNCTION 
 
 
 
 
 
Thom P. Santisakultarm1, Claire Q. Paduano1, Jane Y. Lee1, Teresa L. Southard2, 
Tracy Stokol3, Nozomi Nishimura1, William L. Olbricht1,4, Richard T. Silver5, 
Andrew I. Schafer5, Chris B. Schaffer1 
1Department of Biomedical Engineering, Cornell University, Ithaca, NY 14853 
2Department of Biomedical Sciences, Cornell University, Ithaca, NY 14853 
3Department of Population Medicine and Diagnostic Center, Cornell University, 
Ithaca, NY 14853 
4Department of Chemical and Biomolecular Engineering, Cornell University, Ithaca, 
NY 14853 
5Department of Medicine, Weill Cornell Medical College, New York, NY 10065 
 
This research is a manuscript, which will be submitted to a peer-reviewed journal  
88 
ABSTRACT 
Essential thrombocythemia (ET) and polycythemia vera (PV) are among the 
myeloproliferative neoplasms (MPNs), a group of disorders that exhibit bone marrow 
hyperactivity. Both ET and PV share a common JAK2V617F mutation in hematopoietic 
cells, leading to excessive production of platelets in ET, and red blood cells (RBCs), 
leukocytes, and platelets in PV. The additional blood cells alter rheology and lead to 
prominent coagulation problem of large vessels in ET and PV. Although evidence 
suggests cerebral microcirculation problems in these conditions as well, direct 
observations of microvessel thrombosis or flow problems have not been made. 
Because disruption to cortical circulation is linked to cognitive decline and dementia, 
we utilized in vivo two-photon excited fluorescence (2PEF) microscopy to examine 
cerebral microcirculation of JAK2V617F MPN transgenic mice that mimic the 
phenotypes of ET and PV. As much as 40% of cortical capillaries in MPN models had 
no blood flow. In mice with erythrocytosis, the proportion of stalled capillaries 
increased as hematocrit increased. In ET mice, neither hematocrit, leukocyte, nor 
platelet counts influenced the rate of capillary stalling. In both MPN models, 
leukocytes and platelets played a major role in adhering to the endothelium and 
plugging the microvascular flow. They persisted and chronically obstructed blood 
flow in individual vessels for over 2 hours in some cases. Aspirin did not resolve the 
microocclusions. Our study suggests cerebral microvascular circulation problems may 
be a prominent feature of clinical ET and PV. 
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INTRODUCTION 
Essential thrombocythemia (ET) and polycythemia vera (PV) are two of the 
four myeloproliferative neoplasms (MPNs), the others being myelofibrosis and 
chronic myelogenous leukemia. These diseases exhibit hyperactivity of the bone 
marrow, resulting in an increase in the formed elements of the blood(1). A mutation in 
JAK2, a cytoplasmic tyrosine kinase in the signal transducers and activators of 
transcription (STAT) signaling pathway, was discovered as a common mutation in 
MPNs. ET and PV display the most significant amount of this JAK2V617F mutant allele 
burden among MPNs, with 95% and 60% of patients having mutant protein in 
hematopoietic stem cells, respectively(2). Normally, STAT molecules are 
phosphorylated by activated JAK2 only after binding of a signaling molecule such as 
erythropoietin or thrombopoietin. Phosphorylated STAT then translocates to the 
nucleus, promoting production of blood cells. With mutant JAK2V617F, however, 
STAT phosphorylation is constitutively turned on, regardless of an extracellular signal 
presence, leading to the excess hematopoiesis in MPNs(2). Higher levels of JAK2V617F 
in transgenic mice and human patients has resulted in a PV phenotype, which exhibits 
increases in red blood cells (RBCs), leukocytes, and platelets. On the other hand, 
lower levels of the mutant gene are found in ET, which shows primarily excessive 
platelet production(3).  
 
Both ET and PV display a number of secondary clinical conditions related to 
blood circulation and coagulation problems. In fact, various types of venous, arterial, 
and microvascular thrombosis are the most common causes of morbidity and 
90 
mortality(4). In PV, excess RBCs contributes to high viscosity that increases flow 
resistance(5), and elevated leukocyte counts may also exacerbate flow problems, 
especially in the microvessels where leukocytes must squeeze through vessels and 
contribute significantly to resistance. In both disorders, elevated platelet counts may 
alter lead to increased thrombosis. In the brain, decreased blood flow and vascular 
thrombosis can have devastating consequences. Occlusion of large vessels is a 
common complication of ET and PV that leads to transient ischemic attacks and 
cerebral infarcts(6, 7). Small vessel occlusions are also plausible. Although they may 
not produce acute clinical symptoms, and hence go unnoticed; micro-occlusive events 
may have an important impact on neuronal health. Small stroke is associated with 
cognitive decline and development of dementia such as Alzheimer’s disease and 
vascular dementia(8). Indeed, clinical case studies have linked cognitive problems to 
ET and PV, suggesting neurological effects in these diseases(9-12). 
 
However, because of the lack of robust animal models of MPNs until recently, 
no clear causative link between ET and PV and neural health has been made, and the 
role of elevated hematocrit, leukocytes, and platelets on cerebral microvascular flow 
remains largely unexplored. In order to quantify the effects of PV and ET on the brain, 
we examined vascular structure and cerebral blood flow in MPN mouse models using 
two-photon excited fluorescence microscopy (2PEF), which enables micrometer-
resolution, three-dimensional imaging deep into the brain tissue. We examined 
wildtype, erythropoietin-injected (Epo-inj), and ET and PV mouse models. In order to 
create ET and PV mouse models with JAK2V617F mutation only in the hematopoietic 
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cells, we transplanted the bone marrow cells of transgenic donors with ubiquitous 
mutated JAK2 into wildtype recipients. Strikingly, we found a high incidence of 
stalled blood flow in individual capillary segments in both ET and PV mouse models. 
In PV animals, the number of stalled microvessels increased with increasing 
hematocrit, although leukocytes and platelets were frequently identified as the cause 
of the blockages. We found marked upregulation of intercellular adhesion molecule 
(ICAM)-1, both in vivo and ex vivo, which may have led to leukocyte and platelet 
activation and adhesion to the cerebral vasculature. In the PV models, but not in ET, 
we found evidence of compromised blood brain barrier. Vessel diameter, volume, and 
RBC flow speed were examined and found to be modestly altered in PV and ET.   
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MATERIALS AND METHODS 
Animal Models  
Five experimental groups of animals were utilized in this study: wildtype (wt), bone 
marrow transplanted (BMT) wt, Epo-inj wildtype, BMT ET, and BMT PV. All mice 
were on C57/Bl6 background. The Epo-inj group received 0.5 mL of erythropoietin 
(20 - 200 IU/mL) subcutaneously for 5 consecutive days to induce erythrocytosis. This 
group served as the secondary polycythemia model. Both BMT ET and BMT PV 
groups were derived from mutant JAK2V617F mice, kindly provided by Dr. Radek 
Skoda(3). These transgenic mice were generated using nine copies of the human 
JAK2V617F gene with the sequences placed in the inverse orientation and flanked by 
antiparallel loxP sites. MxCre transgene was crossed into the mouse line in order to 
control FF1 gene activation. These mice were used as bone marrow transplantation 
donors in order to create mice where the JAK2V617F mutation is only present in the 
hematopoietic stem cells, rather than in all cells. Induction of the transgene in BMT 
ET and BMT PV groups made use of interferon-inducible MxCre. By administering 
polyinosine-polycytosine (pIpC, 0.3 mL of 1 mg/mL) intraperitoneally, Cre 
recombinase excise, reorient the transgene, and initiate the constitutive production of 
additional blood cells. We delivered pIpC in one of the two ways:  to the donor prior 
to BMT to obtain recipients with all same phenotype (either ET or PV), or to BMT 
recipient mice after they have recovered from the irradiation. Within 8 to 12 weeks 
after JAK2V617F has been activated, mice with spun hematocrit above 55% were 
classified as PV; those with platelets above 1,000 thou/µL but without elevation of 
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RBCs were considered ET. Mice that did not exhibit the classical symptoms of ET and 
PV were excluded from this study. To control for the effects of bone marrow 
transplantation procedure to subjects’ physiology, we created an experimental group 
where lethally irradiated wildtype mice received normal bone marrow cells from 
another wildtype control donor. Characteristics of subjects are summarized in Table 
5.1. 
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Table 5.1. Characteristics of study subjects 
          
 
wt and BMT wt BMT ET Epo-inj BMT PV 
         
Subjects (n) 35 16 19 14 
Male/Female 29/6 13/3 9/10 4/10 
Age (months) 4.7 (0.4 - 7.6) 5.2 (4 - 12.6) 4.5 (0.8 - 19.7) 5.4 (4.1- 6.5) 
Weight (g) 26 (20 - 36) 27 (20 - 33) 24 (18 - 28)* 23 (19 - 28)* 
Hematocrit (%)** 46 (38 - 52) 46 (39 - 50) 61 (40 - 71)* 67 (54 - 91)* 
Hemoglobin (g/dL) 15.6 (14.1 - 17.2) 16.3 (13.3 - 18.7) 21.1 (19.7 - 21.5) 24.3 (15.2 - 30.7)* 
Red blood cells (mil/µL) 10.5 (9.2 - 11.6) 11.1 (7.4 - 13.7) 14.4 (13.9 - 14.9)* 14.9 (10.1 - 18.4)* 
Leukocytes (thou/µL) 5.0 (3.1 - 10.2) 10.7 (5.8 - 71.8) 3.5 (1.5 - 9.6) 8.3 (7.6 - 35.0) 
Platelets (thou/µL) 882 (787 - 1007) 6226 (1340 - 8019)* 574 (154 - 850) 531 (109 - 1190) 
     Values are expressed as median (range) 
*p < 0.05 vs. control group (one-way ANOVA with multiple comparisons and Tukey-Kramer method) 
**Packed cell volume 
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Bone Marrow Transplantation 
Recipients were irradiated with 5-Gy gamma ray twice at one-hour interval. 
Donors received a pentobarbital (intraperitoneal, 12 mg per 100-g rodent) overdose. 
Bone marrow cells were harvested from their femurs, resuspended in phosphate 
buffered saline (PBS) and retroorbitally administered to recipient mice. The 
transplantation was performed with the donor:recipients ratio of 1:8 to ensure that 
each recipient received at least 2 million bone marrow cells. The recipients were 
allowed to rest and recover for at least 5 weeks after the procedure. 
 
Surgical Preparation 
We follow the surgical procedures previously published(13). A total of 55 
male and 29 female adults (mean ± standard deviations, 5.3±2.5 months-old), 18 - 36 
g in mass were used in this study. Subjects were anesthetized with 2% isoflurane and 
maintained at 1 - 2.5% at 37.5 °C body temperature with a heating blanket (model 50-
7053P; Harvard Apparatus) throughout the experiment. Mice received glycopyrrolate 
(0.05 mg per 100-g rodent) intramuscularly to facilitate respiration. Bupivacaine (0.1 
mL, 0.125% w/v) was subcutaneously administered as a local anesthesia before initial 
incision and preparation of a 5-mm craniotomy over the parietal cortex. A glass cover 
(Deckglaser; World Precision Instruments) was glued to the skull using cyanoacrylate 
(model name; Loctite®) and dental cement (Lang Dental Mfg. Co. & Co-Oral-Ite 
Dental Mfg. Co.), and the space between the exposed brain and the cover glass slip 
was filled with artificial cerebrospinal fluid. For acute experiments, subjects were 
supplemented with 5% (w/v) glucose in physiological saline (0.5 mL per 100-g 
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rodent) hourly throughout the experiment. For chronic experiments, animals received 
dexamethesone (0.02 mg per 100-g rodent) intramuscularly to suppress inflammatory 
response. Subjects received analgesic ketofen (0.2 mg per 100-g rodent) daily or as 
needed for 3 days and were allowed to recover. The care and experimental 
manipulation of our animals have been reviewed and approved by the Institutional 
Animal Care and Use Committee at Cornell University. 
 
Fluorescent Labeling 
Texas red dextran (0.05 mL of 2.5% w/v, D1830; Invitrogen) and Rhodamine 
6G (0.05 mL of 0.1% w/v) in saline was injected retroorbitally. The Texas red dextran 
labels the blood plasma, allowing imaging of vascular topology and quantification of 
blood flow by tracking the motion of non-labeled red blood cells. The lipophilic 
Rhodamine 6G labels both white blood cells and platelets with very high 
efficiency(14). In some experiments, Hoechst 33342 (0.05 mL of 0.5% w/v, H1399; 
Invitrogen) was also intravenously administered to label nuclei of blood cells (i.e. 
leukocytes). 
 
In Vivo Two-photon Excited Fluorescence Imaging 
Cerebral vasculature was imaged using a custom-built 2PEF microscope with 
800-nm, 87-MHz, 100-fs pulses from a Ti:sapphire laser oscillator (MIRA HP 
pumped by a Verdi-V18; Coherent, Inc.) or 1040-nm, 1-MHz, 300-fs pulses from a 
Yb-fiber chirped pulse amplifier (FCPA µJewel D-400; IMRA America, Inc.). The 
fluorescence collected from the sample was split by a 600-nm long-pass dichroic into 
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photomultiplier tubes for dual channel imaging of multiple wavelengths. The 
excitation signal was relayed through filters 460/50, 575/25, and 645/65 nm 
(center/bandwidth), for Hoechst 33342, Rhodamine 6G, and Texas Red imaging, 
respectively. Laser scanning and data acquisition was controlled by MPSCOPE(15) or 
ScanImage(16). A 4x air objective (Olympus) with a 0.28 numerical aperture (NA) 
was used for low magnification images of the cranial window. For high magnification 
imaging of RBC flow speed, vessel diameter, and stall vessel measurements, we used 
a 0.95-NA, 20x water immersion objective (Olympus). 
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Figure 5.1. In vivo 2PEF imaging of cortical microvessels 
(A) Schematic drawing of a cranial window to allow optical access to the brain of an 
anesthetized rodent. (B) Low (4x air objective, NA = 0.28, Olympus) and (C) high 
(20x water immersion objective, NA = 0.95, Olympus) magnification images of 
fluorescently labeled brain vasculature. The images were obtained using a custom-
built 2PEF microscopy, and axially projected using ImageJ (National Institutes of 
Health). (D) Three-dimensional rendering (Imaris; Bitplane Scientific) of the 
vasculature beneath (C). 
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Stalled Vessels Evaluation 
Multiple, high-resolution, overlapping 200 x 200 µm stacks with 1-µm axial 
spacing up to 350 µm in cortical depth were recorded, then aligned in three-
dimensions by maximizing the cross-correlation signals in the overlapping regions to 
obtain vascular topology. Each capillary segment in the combined image volume was 
manually scored to be flowing or stalled, while keeping track of the total capillary 
number for vascular density per brain volume calculation. Vascular segments with 
blood cell movement over 1-s of recording were classed as flowing; while others were 
classed as stalled. This measurement only identifies vessels with no moving blood 
cells, as we cannot determine motion of plasma. Stalled capillaries were categorized as 
associated with platelets if immobile platelets, which contain Rhodamine 6G signal, 
were present within the segment. Stalled capillaries with stationary leukocytes, 
distinguished by colocalization of both Rhodamine 6G and Hoechst33342 signals, 
were denoted as associated to leukocytes. Stalled capillaries without leukocytes or 
platelets were classed as empty or RBCs if stationary RBCs are present. In some 
animals, only Texas red dextran and Rhodamine 6G were present. Platelets and 
leukocytes, both labeled by Rhodamine 6G, can still be distinguished based on their 
appearance. Leukocytes are larger and show solid fluorescence throughout the cell 
where as platelets are much smaller and tend to sporadically aggregate along vessel 
walls and present a more punctate appearance. The capillaries plugged by leukocytes 
or platelets were monitored over the next ~2 hours by examining subsequent image 
stacks acquired at 15, 30, 60, and 120 minutes later at the same region. We determined 
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whether initially blocked vessels by leukocytes or platelets did or did not reestablish 
flow over time. 
 
RBC Flow Speed and Vascular Diameter 
We measured blood flow speed and diameter of surface vessels and their 
connecting microvessels up to 10 branches away. To measure RBC velocity, we 
repetitively scan single vessels along their central axis at a line rate of 1.7 kHz to track 
RBC position over at least 30 s. The obtained space-time images contain diagonal dark 
streaks of the RBC movement over time where the slope is inversely proportional to 
its speed(13, 17, 18). To determine vessel diameter, images of individual vessels were 
recorded while stepping from above to below the vessel. Once axially projected, 
diameters were calculated by manual selection of a cross-sectional line perpendicular 
to the vascular segment. The intensity profile along the selected line was plotted, and 
the diameter was taken to be the distance over which the intensity exceeds 20% of 
maximum intensity value(13). 
 
Blood and Bone Marrow Evaluation 
Subjects were euthanized with pentobarbital (intraperitoneal, 12 mg per 100-g 
rodent) after imaging session, and a minimum of 0.2 mL of whole blood sample was 
drawn into an ethylenediaminetetraacetic acid (EDTA, 0.15 mL of 6.7 mg/mL) 
prefilled syringe by cardiocentesis. The sample was transferred to an EDTA dried-
spray blood collection tube (367842; Becton Dickinson) in order to obtain the 
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complete blood count (Advia 2120; Siemens). Blood smears were made and manually 
evaluated. 
 
Subjects were fixed in 4% paraformaldehyde. The femurs were isolated for 
bone marrow examination, and the brain was kept for immunohistochemical staining. 
Anatomical necropsy was performed on the preserved body to confirm physiological 
manifestation of MPNs (e.g. splenomegaly, hepatomegaly, myeloid hyperplasia, 
fibrosis).
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RESULTS 
 
Micro-occlusive events in mouse models of MPNs 
To study how brain vasculature and blood flow is altered in MPN, we prepared 
glass-covered craniotomies in mouse models of PV and ET, and then used 2PEF 
imaging of intravenously-injected fluorescent dye to acquire three-dimensional image 
stacks of the cortical vasculature (Figure 5.1). Because the dye labels only the blood 
plasma, and not RBCs, we were able to manually score each capillary in the image 
stack as flowing or stalled, based on the whether RBC motion was observed over the 
~4 frames (~1 s) that each capillary was visible in the image stack (Figure 5.2A).  
 
In wildtype animals and in wild type animals that received bone marrow 
transplant from a wildtype animal, we found that the vast majority of brain capillaries 
were flowing, with only a small fraction stalled (mean ± standard error of the mean 
(SEM), 3±0.6%, 5,167 vessels, n = 17). In contrast, we found a marked elevation in 
the number of stalled capillaries in mice with mutant JAK2 in hematopoietic cells that 
exhibited an ET phenotype (16±5%, 4,692 vessels, n = 8), and an even more dramatic 
elevation in capillary stalls in both the Epo-injection model of erythrocytosis (19±4%, 
5,840 vessels, n = 15) and in animals with mutant JAK2 that exhibit a PV phenotype 
(28±5%, 8,959 vessels, n = 11) (Figure 5.2B). There was no significant difference 
between wt and BMT wt groups (S Figure 5.1) or between sexes (S Figure 5.2) 
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In addition, we found the large variability in the fraction of brain capillaries 
stalled in both models with excessive erythrocytosis to depend strongly on the 
hematocrit of the animal (Figure 5.2C). In the ET animals, the fraction of stalled 
capillaries did not appear to depend on hematocrit (Figure 5.2C), platelet, nor 
leukocyte counts (S Figure 5.3). 
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Figure 5.2. Elevated capillary occlusions (“stalls”) in mouse models of MPNs 
(A) Sequential 2PEF images that demonstrate flowing (left panels) and stalled (right 
panels) vessels in the cerebral cortex captured every 0.3 s for a total of 1 s. Texas Red 
dextran was administered to label blood plasma (bright), leaving the cellular 
components unlabeled (dark). (B) Fraction of capillaries with no RBC flow in wt and 
BMT wt, BMT ET, Epo-inj, and BMT PV animals. (C) The fraction of capillary stalls 
increases with increasing hematocrit in Epo-inj and BMT PV animals. The fraction of 
capillaries stalled in BMT ET group was not dependent on hematocrit. 
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Leukocytes and platelet aggregation obstruct microvascular flow in PV and ET 
models, while RBCs block capillaries in PV 
To identify the cellular basis for these stalled capillaries, we developed a 
strategy to distinguish between several potential causes: adhered leukocytes, micro-
thrombi, just stagnant RBCs, or a vessel filled with blood plasma and no flowing 
RBCs (Figure 5.3A). Leukocytes contribution to total capillary stalls were highest in 
BMT PV (5%), followed by Epo-inj (2%), BMT ET (2%), and wt and BMT wt (1%), 
respectively. Platelet stalls also displayed a similar trend with BMT PV being the 
highest (7%), followed by Epo-inj (4%), BMT ET (2%), and wt and BMT wt (1%). 
Both experimental groups with erythrocytosis showed a profound proportion of 
capillaries stalled with only stagnant RBCs (13% and 12% for Epo-inj and BMT PV, 
respectively), compared to animals with normal hematocrit (3% for both BMT ET and 
wt and BMT wt). The rest of the stalled vessels were empty of blood cells (2, 4, 7, and 
4% in wt and BMT wt, BMT ET, Epo-inj, and BMT PV, respectively) (Figure 5.3B; 
wt and BMT wt:  4,061 vessels, n = 11. BMT ET:  3,451 vessels, n = 6. Epo-inj:  
4,640 vessels, n = 8. BMT PV:  6,005 vessels, n = 9). Proportion of stall types among 
only stalled vessels (as oppose to all capillaries) is also available in S Figure 5.5. 
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Figure 5.3. Microvascular stalls in PV and ET are associated with leukocytes and 
platelet aggregates and, in PV models, with RBC plugs 
(A) Four classes of microvascular stalls are distinguished: platelets, leukocytes, only 
RBCs, or empty. Texas Red dextran labeled blood plasma (red), Rhodamine 6G 
labeled leukocytes and platelets (green), while Hoechst33342 bound to nuclei (blue). 
Leukocytes and platelets have distinct morphologies that can be differentiated from 
one another even with the lack of Hoechst33342 dye. RBCs were unlabeled and 
appeared dark against the labeled blood plasma in each vessel. (B) Composition of 
stall causes in wt and BMT wt, BMT ET, Epo-inj, and BMT PV. 
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Estimation of leukocyte and platelet stalls lifetimes 
We monitored each capillary stalled due to a leukocyte or platelet aggregate. 
Over the same region of interest, image stacks were acquired at approximately 15, 30, 
60, and 120 mins after the first time point. We quantified the fraction of microvessels 
where leukocytes and platelets remained in place. Figure 5.4 shows the proportion of 
persistent leukocyte (Figure 5.4A) and platelet (Figure 5.4B) stalls, each fitted to an 
exponential decay. The mean lifetimes of leukocyte plugs were longest in BMT ET 
(15 mins; 81 stalls, n = 7) and BMT PV (7 mins; 24 stalls, n = 5), compared to only 2 
mins for Epo-inj (53 stalls, n = 7) (Figure 5.4A). Platelet stalls reestablish flow 
quickly in BMT ET (2 mins; 110 stalls, n = 5), but 20% that did not resolve and 
remained in place for over 2 hours. In Epo-inj (95 stalls, n = 7) and BMT PV (99 
stalls, n =7), platelet aggregates persisted longer, for 12 and 42 mins, respectively. 
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Figure 5.4. Leukocyte and platelet plugs in cortical capillaries are long-lived 
Individual microvascular stalls associated with leukocytes and platelets were 
monitored. Proportion of persistant (A) leukocytes and (B) platelet aggregates decay 
over time. The mean lifetime of leukocytes and platelets were longest in BMT PV 
compared to BMT ET and Epo-inj animals. After 2 hours, approximately 80% of these 
stalls have reestablished flow. 
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Quantification of average RBC flow speed  
Positions of RBCs in flowing blood vessels were tracked over at least 30 s by 
repetitive line scanning along the centerline of vascular lumen (Figure 5.5E). 
Centerline RBC flow speeds of surface arterioles significantly decreased by 30% in 
Epo-inj (mean ± SEM, 3.9±0.04 mm/s, 72 vessels, n = 12) and 52% in BMT PV 
(2.7±0.07 mm/s, 29 vessels, n = 7), respectively, when compared to wt and BMT wt 
(5.6±0.03 mm/s, 126 vessels, n = 26; one-way ANOVA with multiple comparisons 
using Tukey-Kramer’s method, p = 0.00001). Surface arteriole RBC flow speed in 
BMT ET group did not change significantly (5.3±0.6 mm/s, 41 vessels, n = 7) (Figure 
5.5F). For capillaries, RBC flow speed significantly slowed by 24% in BMT PV 
(0.63±0.04 mm/s, 77 vessels, n = 7) when compared to wt and BMT wt (0.83±0.04 
mm/s, 149 vessels, n = 18; p = 0.0002), while BMT ET (0.78±0.03 mm/s, 92 vessels, 
n = 6) and Epo-inj (0.85±0.03 mm/s, 76 vessels, n = 12) groups were not statistically 
different (Figure 5.5G). Lastly, no statistical difference (p = 0.23) in the mean 
centerline RBC flow speeds of surface venules between wt and BMT wt (1.58±0.10 
mm/s, 141 vessels, n = 27), BMT ET (1.70±0.24 mm/s, 40 vessels, n = 6), Epo-inj 
(1.72±0.13 mm/s, 106 vessels, n = 12), or BMT PV (1.14±0.22 mm/s, 25 vessels, n = 
7) groups was found (Figure 5.5H). 
 
Average vascular diameter 
We measured diameter of surface arteriole, cortical capillaries, and surface 
venules (Figure 5.5A). There was no significant difference in diameters of surface 
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arterioles for the BMT ET (15.6±1.9 µm, 51 vessels, n = 9), Epo-inj (21.2±1.6 µm, 70 
vessels, n = 12), or BMT PV (20.5±2.4 µm, 31 vessels, n = 7) groups when compared 
to wt and BMT wt (20.5±1.2 µm, 120 vessels, n = 26) (one-way ANOVA with 
multiple comparisons using Tukey-Kramer method, p = 0.52) (Figure 5.5B). Capillary 
diameter of BMT PV (5.3±0.1 µm, 96 vessels, n = 7) was significantly larger than 
those of BMT ET (4.8±0.1 µm, 118 vessels, n = 8) and Epo-inj (4.6±0.1 µm, 110 
vessels, n = 12), but not wt and BMT wt (4.9±0.1 µm, 180 vessels, n = 18, p = 0.0005) 
(Figure 5.5C). Diameter of surface venules in Epo-inj group (34.0±3.2 µm, 111 
vessels, n = 12) was larger than wt and BMT wt group (22.1±1.9 µm, 134 vessels, n = 
27, p = 0.01) (Figure 5.5D).  
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Figure 5.5. Diameter and speed of microvessels in MPNs 
(A) Axially projected images of a single microvessel and its intensity profile along the 
drawn line. Diameter was taken to be the distance over which the intensity exceeds 
20% of maximum intensity value. Diameter of surface arterioles (B), capillaries (C), 
and venules (D). (E) Schematic drawing of linescan acquisition to track RBC positions 
over time and obtain blood flow velocity in individual blood vessels. Speed of surface 
arterioles (F), cortical capillaries (G), and surface venules (H).   
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Quantification of capillary density 
Capillary density in wt and BMT wt (mean ± standard deviation, 8,937±1,492 
vessels/mm3), BMT ET (8,030±727 vessels/mm3), Epo-inj (9,897±3,073 
vessels/mm3), and BMT PV (8,890±1,615 vessels/mm3) were not statistically different 
from one another (one-way ANOVA with multiple comparisons using Tukey-Kramer 
method, p = 0.48). 
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DISCUSSION 
We quantified the proportion of stalled capillaries in the brain of MPN mouse 
models and found an elevation in microvessels with no flow (Figure 5.2). In brain 
surface vessels, all larger than ~7 µm, no flow blockage was observed, although large 
thrombosis (e.g. deep vein thrombosis(19), heart attack(20), and stroke(21)) is a 
known complication in humans with MPNs. Our study showed the first direct 
observation of cerebral microvessel thrombosis in live animal models of MPNs. The 
chronic micro-occlusions of cortical vascular network are a potential cause of small 
strokes. They can disturb efficient transport of nutrition, waste, and oxygen, which is 
detrimental to neural health. Studies have also shown that small strokes are associated 
with neurological degeneration and cognitive decline(8). This may explain 
neurological symptoms such as depression(9), mixed movement disorder(10), 
amnesia, headache, and dysphagia(11) displayed in ET and PV patients. Stroke and 
cerebral embolism are also prevalent in both ET(12) and PV(7)—observations that are 
also consistent with ours.  
 
Further, we identified leukocyte and platelets to be associated with a large 
proportion of overall stalled blood vessels. In PV, this overactivation is related to high 
hematocrit(22) (Figure 5.2), which leads to enhanced cellular interactions due to red 
cell mass expansion(23, 24). High hematocrit also results in high viscosity and shear 
rate on the vessel wall, leading to endothelial dysfunction(24, 25). Our finding 
demonstrated leukocyte activation and tight adherence to damaged endothelium that 
plugged capillary blood flow.  
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On the other hand, the factors that influence thrombotic risks in ET are less 
clear in previous studies as well as in ours (Figure 5.2C and S Figure 5.3). The 
degree of thrombocytosis did not correlate with thrombosis in our study, and was 
found to be an inconsistent variable associated with thrombosis in others(25, 26). 
Leukocytosis, however, was shown by many clinical studies to increase thrombotic 
risk and is an independent predictor of leukemic transformation in ET(27, 28). 
Nevertheless, because platelet cytoreduction therapy seems to reduce thrombotic 
frequency in high-risk ET patients, there is a belief among physicians that normal 
platelet count is preferable. Regardless of the explanation, leukocytes and platelets 
activation in both ET and PV have been observed in vitro and in vivo(29). CD11b, an 
antigen that mediates adhesion during inflammation, is overexpress, thus leading to 
greater capacity for phagocytosis as well as increased production of reactive oxygen 
species(30). In ET, the percentage of platelets expressing P-selectin is increased in 
patients with a history of thrombosis compared to those without. ET patients are also 
more likely to have an increase in E-selectin and circulating microparticles, produced 
by platelets, which amplify thrombogenesis(31, 32). Furthermore, prothrombin 
fragment, thrombomodulin, and von Willebrand factor were found to be elevated in 
both PV and ET. Platelet and leukocyte activation results in an increase in circulating 
platelet-leukocyte complexes, which is reported to correlate with neutrophil 
degranulation, stabilization of fibrinogen, and higher extracellular tissue factor 
content(33, 34). Thus, prothrombotic flow environment is constituted and greatly 
affected microcirculation(32, 35, 36). 
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For blood vessels with flowing RBCs, there is an overall trend for slower flow 
speed in the animal models of MPNs, with severity most pronounced in high 
hematocrit Epo-inj and BMT PV animals (Figure 5.5). On average, diameter of 
arterioles, capillaries, and venules were not largely different. Vascular density also did 
not change significantly when compared to wt and BMT wt. In combination with the 
proportion of stalled capillaries and the decrease in flow speed in the still-flowing 
vessels, we approximate the decrease in capillary bed perfusion to be 30, 17, and 34% 
in BMT ET, Epo-inj, and BMT PV, respectively compared to controls. While this 
flow reduction is not likely to cause an explicit stroke, such chronic hypoperfusion due 
to, for example carotid artery stenosis, has been linked to accelerated cognitive 
decline(38-40). Thus, microthrombotic events in MPNs may have detrimental impact 
to neural function in the long term. 
 
We have demonstrated impaired cerebral blood flow in the brain of MPN 
mouse models using 2PEF microscopy. In PV models, elevated capillary stalls 
strongly correlated with increased hematocrit. Therefore, hematocrit level must be 
carefully controlled to minimize small strokes. In ET, however, further studies are 
required to identify the critical factors that lead to thrombotic complications in the 
microvessels. In both disorders, leukocytes, platelets, and endothelium were activated 
and played a major role in disturbance to normal brain blood flow. Careful assessment 
116 
of cognitive functions and novel targeted therapy to decrease stalls would be 
beneficial to decrease neurological problems in MPN patients. 
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SUPPLEMENTARY FIGURES 
 
 
 
 
Supplementary Figure 5.1. Capillary stalls in wt and BMT wt animals are 
comparable 
There was no statistically significant difference between the proportion of stalled 
capillaries in wt and BMT wt groups. 
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Supplementary Figure 5.2. Capillary stalls comparisons between male and 
females 
The rates of capillary stalls are not statistically significant except in the case of wt and 
BMT wt males and females 
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Supplementary Figure 5.3. Proportion of stalled capillaries as a function of 
leukocyte and platelet counts 
Leukocytes and platelet counts did not correlate to the stall rate of wt and BMT wt, 
BMT ET, Epo-inj, nor BMT PV 
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Supplementary Figure 5.4. Stall compositions by causes 
Stall compositions were shown by stall types:  empty, leukocyte, platelet, or RBC 
plugs. 
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CHAPTER 6 
CEREBRAL BLOOD FLOW ABNORMALITIES IN ANIMAL MODELS OF 
SICKLE CELL DISEASE 
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PATHOPHYSIOLOGY OF SICKLE CELL DISEASE 
Sickle cell disease (SCD) is a group of heritable hemoglobinopathies resulting 
most often in sickle hemoglobin (HbS) (Table 6.1). About 50,000 Americans are 
affected by SCD, and it is estimated that 2 million more are carriers for the trait. SCD 
affects primarily those of African descent, with 8-10% of the African American 
population being carriers (1). Even higher frequencies are found in African 
populations, particularly in equatorial regions. The high frequency of carriers is 
thought to be due to the heterozygous advantage the gene confers to malaria infection. 
 
In HbS, a single point mutation of the 17th nucleotide leads to the substitution 
of valine for glutamine in the β-globin chain. This substitution causes the β1 and β2 
chains of two hemoglobin molecules to crystallize when the HbS tetramer is 
deoxygenated, so that deoxygenated HbS polymerizes into fibers which disturb the 
normal morphology of red blood cells (RBCs) causes them to “sickle” into a 
characteristic crescent-shape (Fig. 6.1). As RBCs enter the microvasculature, they 
gradually become deoxygenated and increasingly rigid and sickled. This increases 
blood viscosity, increases shear rate, hence reducing flow speed through individual 
microvessels. The increased transit time leads to further deoxygenation that reduces 
deformability of the cells, resulting in blockages of microcirculation (Fig. 6.2). The 
most common variant of SCD is sickle cell anemia (SCA), in which patients are 
homozygous for the β-globin mutation (genotype βSβS). SCA is characterized by 
chronic hemolytic anemia and vaso-occlusive crisis leading to progressive tissue 
damage in highly vascularized organs including the liver, kidney, brain, and lungs (1).  
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Table 6.1:  Different types of SCD (1) 
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haemolysis. Free plasma haemoglobin generates reactive 
oxygen species, such as the hydroxyl and superoxide 
radical,41 which is a potent scavenger of nitric oxide.42 Nitric 
oxide is normally produced by the endothelium and 
regulates basal vasodilator tone, and inhibits platelet and 
haemostatic activation and transcriptional expression of 
nuclear factor κB (NF κB)-dependent adhesion molecules, 
such as vascular cell-adhesion molecule-1, intercellular 
cell-adhesion molecule-1, and the selectins.43,44 The release 
of haemoglobin into the plasma during haemolysis 
potently inhibits endothelial nitric oxide signalling, leading 
to endothelial cell dysfunction and nitric oxide resistance.42,45 
Haemolysis also releases erythrocyte arginase-1 into 
plasma. Arginase metabolises plasma arginine into 
ornithine, decreasing the required substrate for nitric oxide 
synthesis and compounding the decreased bioavailability 
of nitric oxide in patients with sickle-cell disease.46
Chronic depletion of nitric oxide and arginine might 
also contribute to the hypercoagulable state in haemolytic 
diseases. Studies have shown correlations between the 
rate of haemolysis and levels of platelet activation and 
procoagulant factors in the blood.47 Haemolysis is also 
associated with the formation of erythrocyte microvesicles 
containing phosphatidyl serine, which is an activator of 
tissue factor; the numbers of microvesicles are increased 
further by the functional asplenia present in patients 
with sickle-cell disease48 (fi gure 2).
Epidemiology
The global distribution of HbS is indicative of two 
factors: selection for carriers through their survival 
advantage in malaria-endemic regions and subsequent 
migration. Four region-specifi c African haplotypes (the 
Senegal, Benin, Bantu, and Cameroon haplotypes) and 
one Asian haplotype (the Arab-India haplotype) have 
been defi ned, providing support for the hypothesis that 
the mutation causing HbS has occurred, and been 
locally amplifi ed, on at least two, and possibly several, 
separate occasions.49 The evidence that malaria caused 
this amplifi cation, which was fi rst suggested more than 
60 years ago,50 is now substantial. In addition to the 
close geographic correlation between the frequency of 
the HbS gene in populations and the historic incidence 
of malaria49 (fi gure 3), evidence for the partial resistance 
of carriers to all forms of Plasmodium falciparum malaria 
has been reported in many populations.55,56 Although 
the mechanism of this protection is yet to be fully 
understood, it probably includes both innate and 
immune-mediated mechanisms.57 The genetic defects 
that commonly combine with HbS to result in sickle-
cell disease (HbC and β-thalassaemia) have also occurred 
through malaria selection,49,57 with the result that such 
defects reach their highest frequencies in similar 
populations.49 The prevalence of sickle-cell disease is 
highest in sub-Saharan Africa. Although the scarcity of 
Characteristics
Severe sickle-cell disease
HbS/S (β6Glu>Val/β6Glu>Val); sickle-cell anaemia The most common form of sickle-cell disease
HbS/β⁰ thalassaemia Most prevalent in the eastern Mediterranean region and India14
Severe HbS/β⁺ thalassaemia Most prevalent in the eastern Mediterranean region and India; 1–5% HbA present14
HbS/OArab (β6Glu>Val/β121Glu>Lys) Reported in north Africa, the Middle East, and the Balkans; relatively rare14
HbS/D Punjab (β6Glu>Val/β121Glu>Gln) Predominant in northern India but occurs worldwide14
HbS/C Harlem (β6Glu>Val/β6Glu>Val/β, β73Asp>Asn) Electrophoretically resembles HbSC, but clinically severe; double mutation in β-globin gene; very rare15
HbC/S Antilles (β6Glu>Lys/β6Glu>Val, β23Val–Ile) Double mutation in β-globin gene results in severe sickle-cell disease when co-inherited with HbC; 
very rare16
HbS/Quebec-CHORI (β6Glu>Val/β87Thr>Ile) Two cases described; resembles sickle-cell trait with standard analytical techniques17
Moderate sickle-cell disease
HbS/C (β6Glu>Val/β6Glu>Lys) 25–30% cases of sickle-cell disease in populations of African origin13
Moderate HbS/β⁺ thalassaemia Most cases in the eastern Mediterranean region; 6–15% HbA present14
HbA/S Oman (βA/β6Glu>Val, β121Glu>Lys) Dominant form of sickle-cell disease caused by double mutation in β-globin gene; very rare18
Mild sickle-cell disease
Mild HbS/β⁺⁺ thalassaemia Mostly in populations of African origin; 16–30% HbA present14
HbS/E (β6Glu>Val/β26Glu>Lys) HbE predominates in southeast Asia and so HbSE uncommon, although frequency is increasing with 
population migration19
HbA/Jamaica Plain (βA/β6Glu>Val, β68Leu/Phe) Dominant form of sickle-cell disease; double mutation results in Hb with low oxygen affi  nity; one 
case described20
Very mild sickle-cell disease
HbS/HPFH Group of disorders caused by large deletions of the β-globin gene complex; typically 30% fetal 
haemoglobin14
HbS/other Hb variants HbS is co-inherited with many other Hb variants, and symptoms develop only in extreme hypoxia
Genotypes that have been reported to cause sickle-cell disease are listed. All include at least one copy of the βS allele, in combination with one or more mutations in the 
β-globin gene. HbS=sickle haemoglobin. HbA=haemoglobin variant A. HbE=haemoglobin variant E. Hb=haemoglobin.
Table 2: Diff erent types of sickle-cell disease
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Figure 6.1:  Sickle RBCs 
Four subpopulations of sickle RBCs:  (I) reticulocytes, (II) discocytes, (III) dense 
discocytes, and (IV) irreversibly sickled cells under oxygenated and deoxygenated 
conditions (2). 
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Figure 5
Four subpopulations of sickle red blood cells (RBCs). Scanning electron microscopy images of the four subpopulations of sickle RBCs
in oxygenated and deoxygenated conditions. Reprinted from Reference 48 with permission from the American Society for Clinical
Investigation.
the pressure wave until resistance of the arterioles dampens the pulsatility. Therefore, in the
capillaries, velocities are sufficiently reduced to allow diffusion of oxygen and carbon dioxide to
occur. The flow rate is given by:
Q = !P/R, (4)
where Q is the volumetric flow rate, !P is the pressure differential, and R is the resistance.
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Figure 6.2:  Vicious Cycle Exacerbates Damage of RBCs in Microvasculature 
(a) Schematic of the cycle. (b) Normal RBCs traverse capillaries with high deformity 
and see no changes in viscosity. Sickle RBCs, however, increase their viscosity as 
they deoxygenate, which changes their shape and enter them into vicious cycle (3).  
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Figure 7
Vicious cycle exacerbates damage of highly deformable cells after they enter the microvasculature and are sickled. (a) Schematic of the
cycle. (b) No mal red blood cells (RBCs) traverse capillaries with high deformability and see no changes in viscosity. Sickl RBCs,
however, increase their viscosity as they deoxygenate, which changes their shape and enters them into the vicious cycle.
4) The RBC velocity and deformability decrease.
5) The decreased velocity and deformability increase the amount of time required to pass
through the capillary.
6) Deoxygenation progresses and further advances sickle hemoglobin polymerization.
7) The RBC exits the capillary or contributes to transient or permanent blockage.
Whereas hemoglobin polymerization is reversible, the damage it does to the RBC membrane
is not; this yields deformable RBCs with proadhesive proteins on their surface. The high de-
formability gives them the mechanical properties to enter the capillaries, but once hemoglobin
polymerization begins as they are deoxygenated, their axial ratio is too large for the capillary di-
ameter, and the vicious cycle begins. Interestingly, the rigid, sickled RBCs have been shown not
to enter the capillaries themselves but were stuck at the entrance in animals given human sickle
cells (69) and in studies of retinas of sickle cell patients (70).
3.4. Adhesive Interactions
An extensive body of literature has shown that sickle RBCs are extraordinarily proadhesive (68). An
early and critical observation was that the adhesivity of sickle RBCs for endothelium was strongly
correlated to the clinical severity of disease (71). This finding led researchers to investigate possible
mechanisms of abnormal adhesion. Sickle RBCs are now known to participate in numerous cell-
cell and cell-protein adhesive interactions through their abnormal surface expression of molecules
and receptors as a result of the damage to the cell membrane by the HbS fiber polymerization.
Impedance to blood flow is a key rheologic determinant of SCDpathophysiology, and adhesion
of WBCs increases impedance at low flow (4, 72). Abnormal adhesion of sickle RBCs is another
important contributing factor. Over the past three decades, rheological studies have revealed
that sickle endothelial adherence involves membrane and shape changes (23, 73), is dependent
upon density (10, 73, 74), and occurs predominantly under low-flow (low-shear) conditions of
postcapillary venules (24, 67). Sickle endothelial adherence is also related to disease severity (75)
and supported by clinical studies showing that vaso-occlusive crises are associated with a higher
www.annualreviews.org • Sickle Cell Biomechanics 357
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COMPLICATIONS 
Stroke is the leading cause of death in SCA. Stroke has mainly been 
documented in patients with SCA, rather than in other variants of SCD, with a 
frequency of 6% in patients of all ages. There is a 67% incidence of reoccurrence of 
stroke, with 60% of these occurring within 36 months following the initial stroke (1, 
4). The chance for the first stroke occurring by 20 years of age was reported to be 
11%, rising to 24% by 45 years of age (5). In patients under 20 years of age, as well as 
for those over 30 years of age, the majority of strokes are infarcts and do not result in 
death. On the other hand, in patients 20-29 years of age the majority of strokes are 
hemorrhagic. The mechanisms driving these changing risk profiles remain unclear. 
Most deaths caused by stroke are identified as hemorrhagic (5). The high risk for 
stroke, combined with high rate of reoccurrence and mortality, makes risk factors and 
treatment of stroke obvious areas of study in SCA. Multiple factors may play into risk 
for stroke, as while infants less than 2 years of age seem to be protected from stroke, 
exhibiting the lowest incidence of all age groups, children ages 1 through 9 years of 
age have a higher risk of stroke than those ages 10 through 19 (1). Some risk factors 
that have been suggested to result in cerebrovascular damage are high white blood cell 
count, increased cerebral blood flow, and high flow velocity due to chronic anemia. In 
agreement, our preliminary experiments in SCD mice that were quite anemic found an 
increase in cerebral blood flow speed (Fig. 6.3). The severity of SCA is often 
determined by the severity of anemia, but the correlation between level of anemia and 
risk for serious complications is not well understood (1). The role of leukocytes in 
vaso-occlusive events is also still an active area of investigation.   
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Figure 6.3:  Centerline RBC Flow Speed in the Brain of SCD Mouse Model 
Centerline RBC flow speed of cortical capillaries and venules increased significantly 
compared to wildtype control. 
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 Hemolysis in SCA may also contribute to development of progressive 
vasculopathy characterized by systemic and pulmonary hypertension, endothelial 
dysfunction, and changes in the intima and smooth muscle of blood vessels (1). 
Previous epidemiological studies suggest that several complications are associated 
with increased rates of hemolysis. These conditions include cholelithiasis (or 
gallstones), cutaneous leg ulceration, priapism, and pulmonary hypertension. They 
were also found to be associated with low steady-state hemoglobin concentrations and 
tissue oxygenation (6, 7). An association between the development of pulmonary 
hypertension and the intensity of hemolytic anemia was noted in three prospective 
screening studies of adults with SCD (6, 8, 9) and in pediatric studies (10, 11). 
Pulmonary hypertension has also been reported in other forms of chronic hereditary 
and acquired hemolytic anemia. 
 
VASO-OCCLUSIVE CRISIS 
It is thought that RBCs and leukocytes become trapped in microcirculation 
through physical entrapment or adhesive interactions and obstruct blood flow, leading 
to painful ischemic injury (12). Rigidity of the sickle RBCs and inflammatory 
response may lead to a cycle of temporary occlusions and ischemia, followed by 
reperfusion coupled with increased oxidative and inflammatory stress (Fig. 6.2). This 
may lead to increased expression of endothelial adhesion markers, increased synthesis 
of inflammatory cytokines, and leukocytosis (1)—a mechanism similar to our 
hypothesis in the study of myeloproliferative neoplasms (Chapter 5). Increase in 
dissolved hemoglobin due to hemolysis, and the corresponding inactivation of nitric 
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oxide (NO), also contributes to heightened oxidative stress and excessive 
vasoconstriction (Fig. 6.4) (12). As sickle RBCs have been observed to aggregate with 
platelets, leukocytes, as well as other RBCs, it is unclear to what extent leukocytes are 
responsible for vaso-occlusion, but there is evidence that adherent leukocytes may 
capture circulating RBCs and produce vascular occlusion (13). For example, 
intravenous immunoglobulin administration that suppresses inflammation decreased 
reduced adherent leukocyte numbers, and dramatically inhibited interactions between 
RBCs and leukocytes, resulting in improved microcirculatory blood flow and survival 
of SCD transgenic mice.   
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Figure 6.4:  Steps in Vaso-occlusion in Larger Arteries 
(1) Sickle RBCs adhere to endothelium. (2) Hemolysis. (3) White blood cell adhesion. 
(4) Increased vascular tone. (5) Neointimal proliferation. (6) Platelet aggregation. (7) 
Vasculopathy. (8) Vaso-occlusion. 
ET-1, endothelin-1; NO, Nitric Oxide (14). 
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Figure 9
Steps in vaso-occlusion in large arteries. (1) Sickle red blood cell adherence to endothelium. (2) Hemolysis. (3) White blood cell
adhesion. (4) Increased vascular tone. (5) Neointimal proliferation. (6) Platelet aggregation. (7) Vasculopathy. (8) Vaso-occlusion.
Abbreviations: ET-1, endothelin-1; NO, nitric oxide. Reprinted from Reference 6 with permission from Elsevier.
not defined and may arise from adhered cell aggregates or vascular remodeling, but future studies
are needed for clarification.
5. BIOMECHANICS OF SICKLE CELLS IN ANIMAL MODELS
The in vitro experimental systems described herein provide one lens into the biomechanical
changes that occur in SCD, but the dynamics and complexity of in vivo pathobiomechanics could
not fully be captured. A series of pivotal ex vivo experiments focused on the rheological charac-
teristics of microvasculature, using cat mesentery (99), rabbit omentum (99), and rat cremaster
muscle (100) tomeasure shear stress, shear rate, and RBC velocity as well as the tortuous geometry
of microvessels. With these biomechanical properties characterized, allogeneic models of SCD
were studied through injection of human sickle RBCs into these and other animal microvascula-
ture ex vivo systems. By direct observation of these cells under low shear rate and at low velocities,
adhesion of the sickle RBCs to the microvascular endothelium was visualized for the first time
(5). This led to a succession of ex vivo adhesion experiments that showed the spatial location of
the vaso-occlusions, higher resistance to flow in sickle blood, and correlation of peripheral resis-
tance to adhesion; most important, the experiments showed that cell adhesion is an initial step in
vaso-occlusion (5, 69, 100–102).
The first transgenic sickle mouse was termed the SADmouse. It had three mutations to induce
sickled hemoglobin under hypoxic conditions (103): hemoglobin S (HbS), Antilles b23-I, and D-
Punjab b121-N mutations. Developed in 1989 (104), the SAD mouse was useful for studying the
pathobiomechanical aspects of increased viscosity and vaso-occlusion, but themice exhibited these
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Previous SCA research has mainly focused on organ damage in the spleen, 
kidney, lungs, and liver. The cognitive effects of SCD, on the other hand, have been 
studied mostly in clinical cases. Normal cerebral blood flow is key to robust cognitive 
function in humans. Adequate oxygenation, nutrients delivery, and waste removal are 
necessary for robust tissue function. Regions of tissue death due to low oxygenation in 
the brain have been found in patients suffering from SCA (1, 15). Following stroke, 
many patients show improvement in neurologic function in the year following the 
event, but none recover to their original level of neurologic function. The level of 
cognitive and functional decline following stroke also increased in severity with 
increasing number of reoccurrences of stroke (4). In addition, children with regions of 
cerebral tissue death display impaired cognitive function in tests including language 
ability and spatial memory (15). A deeper understanding of cognitive decline in SCA, 
however, could extend to a more fundamental understanding of the mechanisms that 
link cognitive impairment with cerebrovascular diseases. 
 
PRELIMINARY EXPERIMENTS AND RESULTS 
In our preliminary experiments, we utilized Berkeley sickle cell mice which 
contains human α, βS, Aγ, Gγ, β globin transgene and lack murine α and β globins (α-/-, 
β-/-) as bone marrow cell donors(16). Using bone marrow transplantation procedures 
as described in Chapter 5, the resulting recipient mice exhibit human sickle cells. We 
examined cerebral microcirculation of the SCD mouse models using in vivo two-
photon excited fluorescence (2PEF) imaging approaches from Chapter 4 and 5. So far, 
we have revealed increased RBC flow speed in the cerebral vessels (Fig. 6.3), which 
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correlates to high risk of stroke. In addition, the increase in flow speed modulation 
with heart beat (Fig. 6.5) coupled with a decrease in delay between heart beat and 
peak flow speed (Fig. 6.6) suggests a reduction in vascular distensibility and 
flexibility, especially in capillaries deep in the cortex where vasodilation was also 
found (Fig. 6.7). This chronic vasodilation leads to overall increase in the fraction of 
the brain volume taken up by the vasculature (Fig. 6.8A-F). We did the following 
calculation using the measured vascular volume (Fig. 6.8G) to rule out possible 
angiogenesis. 
 
Since the experimental ratio of !!"!!"# is similar to the calculated value, we concluded 
that the increase in vascular volume in SCD mice is mainly due to chronic 
vasodilation. Lastly, we witnessed some vaso-occlusive events in cortical capillaries, 
although this increase in stalled microvessels is not statistically significant. Overall, 
  
! 
V = proportion of vascular volume
r = capillary radius
L = total vascular length
V " r 2L
Vwt
VSCD
=
rwt
2 Lwt
rSCD
2 LSCD
=
rwt
2
rSCD
2  if Lwt = LSCD
calculated :   
Vwt
VSCD
=
rwt
2
rSCD
2 =
2.602
3.372
= 0.60
experimental :   
Vwt
VSCD
=
0.021
0.033
= 0.64
!
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our preliminary data show promising work for detailed examination of the impact of 
SCD on cerebral microcirculation and vascular structure that may reveal the 
mechanisms of disturbed blood flow in microcircular networks. 
.  
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Figure 6.5:  Speed modulation with heart beat in the brain of SCD Mouse Model 
Speed modulation with heart beat in cortical arterioles and venules significantly 
increased compared to wildtype 
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Figure 6.6:  Delay between heart beat and peak flow speed in the brain of SCD 
mouse model 
Delay between heart beat and peak flow speed decreased significantly in surface 
venule 
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Figure 6.7:  Cerebral microvascular diameter of SCD mouse model 
Cortical capillaries of SCD mice were significantly dilated. 
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Figure 6.8:  Vascular volume in the brain of SCD mouse model 
Low magnification z-projection of cortical vasculature images of wildtype (A), and 
SCD mice (C and E) with their corresponding high magnification images (B, D, and F, 
respectively). The proportion of vascular volume in the brain of SCD mice was 
significantly higher than in wildtype mice (G). 
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Figure 6.9:  Cortical capillary occlusions in SCD mouse model 
A trend of elevated capillary stall in SCD mice was observed, although not statistically 
significant. 
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CHAPTER 7 
CYCLIC STRAIN ANISOTROPY REGULATES VALVULAR 
INTERSTITIAL CELL PHENOTYPE AND TISSUE REMODELING IN 
THREE-DIMENSIONAL CULTURE 
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Gould et al., Cyclic strain anisotropy regulates valvular interstitial cell phenotype and 
tissue remodeling in three-dimensional culture. Acta biomaterialia,  (Jan 11, 2012). 
My specific contribution was second harmonic generation imaging of collagen fibers.  
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ABSTRACT 
Many planar connective tissues exhibit complex anisotropic matrix fiber 
arrangements that are critical to their biomechanical function. This organized structure 
is created and modified by resident fibroblasts in response to mechanical forces in 
their environment. The directionality of applied strain fields changes dramatically 
during development, aging, and disease, but the specific effect of strain direction on 
matrix remodeling is less clear. Current mechanobiological inquiry of planar tissues is 
limited to equibiaxial or uniaxial stretch, which inadequately simulates many in vivo 
environments. In this study, we implement a novel bioreactor system to demonstrate 
the unique effect of controlled anisotropic strain on fibroblast behavior in three-
dimensional (3-D) engineered tissue environments, using aortic valve interstitial 
fibroblast cells as a model system. Cell seeded 3-D collagen hydrogels were subjected 
to cyclic anisotropic strain profiles maintained at constant areal strain magnitude for 
up to 96 h at 1 Hz. Increasing anisotropy of biaxial strain resulted in increased cellular 
orientation and collagen fiber alignment along the principal directions of strain and 
cell orientation was found to precede fiber reorganization. Cellular proliferation and 
apoptosis were both significantly enhanced under increasing biaxial strain anisotropy 
(P < 0.05). While cyclic strain reduced both vimentin and alpha-smooth muscle actin 
compared to unstrained controls, vimentin and alpha-smooth muscle actin expression 
increased with strain anisotropy and correlated with direction (P < 0.05). Collectively, 
these results suggest that strain field anisotropy is an independent regulator of 
fibroblast cell phenotype, turnover, and matrix reorganization, which may inform 
normal and pathological remodeling in soft tissues. 
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GRAPHICAL ABSTRACT 
 
 
 
 
 
 
 
Valvular interstitial cells rapidly reorient orthogonally with biaxial anisotropic 
strain, while modulating directional levels of ACTA2. (A) During isotropic strain, 
orientation of valvular interstitial cells (f-actin, green) align without a preferred 
direction (DNA, blue). (B) During anisotropic strain, cellular orientation aligns with 
respect to the principal directions of strain. (C) A larger degree of ACTA2 expression 
(green) occurs perpendicular to the first principal strain direction (DNA, red). 
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INTRODUCTION 
Planar connective tissues such as the diaphragm, pericardium, and valve 
leaflets perform critical biomechanical functions under cyclic mechanical 
loading (1) and (2). These tissues have evolved complex multidirectional collagenous 
fiber orientations that result in anisotropic mechanical properties ideally suited to their 
local microenvironment. Resident tissue fibroblasts continuously repair and remodel 
their tissue microenvironment in response to these mechanical cues, including 
secreting and/or degrading extracellular matrix proteins, releasing soluble growth 
factors, and reorganizing cell–cell/cell–matrix adhesive interactions (3) and (4). 
Fibroblasts transition between a quiescent synthetic phenotype, characterized by 
homeostatic matrix turnover, to activated contractile myofibroblasts that change the 
underlying matrix mechanics and/or composition depending on the remodeling state of 
the tissue (5). For example, during wound closure and fibrosis/scar formation, 
myofibroblasts elevate expression of contractile proteins and generate traction forces 
that create mechanical tension to pull matrix fibers together (6). Heart valve leaflets 
are exposed to arguably the most demanding mechanical environment in the body, yet 
interstitial fibroblasts thrive and mediate significant matrix turnover (7) and (8). 
Mechanical microenvironmental cues therefore provide strong inductive signals 
regulating tissue homeostasis and remodeling, but how they mediate healthy instead of 
pathological tissue remodeling remains poorly understood. 
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Mechanistic understanding of fibroblast-mediated tissue remodeling has 
advanced considerably with the aid of engineered tissue models that enable testing of 
molecular, cellular, and tissue scale mechanisms within a well-defined, repeatable, and 
physiologically relevant microenvironment (9). Fibroblasts in anchored three-
dimensional (3-D) hydrogels develop mechanical tension leading to increased 
expression of contractile proteins, enhanced matrix synthesis, and release of growth 
factors such as transforming growth factor-beta (TGFβ), while fibroblasts in free-
floating unstressed gels remain quiescent (10). More recently, bioreactors have been 
developed to apply specific mechanical strain parameters uniformly to specimens so as 
to isolate the underlying signaling mechanisms (11). For example, cyclic stretching of 
fibroblasts in vitro induces cytoskeleton rearrangement (12), focal adhesion 
clustering (13), and downstream intracellular signaling cascades leading to cell and 
matrix fiber reorganization (14). While the effects of strain magnitude and frequency 
have been studied for some time, the unique signaling from strain directionality is 
much less known. Cyclic uniaxial (one direction) stretch-induced TGFβ1, collagen III 
and fibronectin gene expression in cardiac fibroblasts. Equiaxial (isotropic) strain, 
however, induced divergent responses in extracellular matrix (ECM) mRNA 
levels (15). Fibroblasts have also been shown to align perpendicular to the direction of 
principal strain, while no-preferred direction occurs during equiaxial strain (16). Given 
that planar tissues experience multi-axial strain patterns in vivo and exhibit anisotropic 
biomechanical properties rather than either of the above extremes (17), it is therefore 
critically important to understand how biaxial strain anisotropy independently affects 
molecular signaling, fibroblast phenotype, and matrix remodeling behavior. 
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While biaxial and even triaxial stretches have been applied to tissues in 
cylindrical configurations, such as blood vessels (18), a similar device for planar 3-D 
engineered tissues has not been developed. Well-defined anisotropic biaxial strain 
fields have to date only been applied to planar cultures on two-dimensional (2-D) 
substrates (19). Biaxial (radial and circumferential) tensile strains can be applied in 
two dimensions using a vacuum-pressure (Flexcell) system, but strain magnitude 
varies in homogeneously with distance from the center of the membrane (20). Tan et 
al. also generated static heterogeneous anisotropic biaxial micro-strain patterns 
through multi spoke and microgroove array patterned 2-D substrates (21). We 
previously showed that smooth muscle cells exposed to homogeneous equiaxial 
stretch in 3-D culture dedifferentiate to synthetic myofibroblasts (22). Studies with 
valve fibroblasts in 3-D culture have shown heterogeneous changes in cell phenotype 
and matrix synthesis, but these could not be directly related to specific strain 
profiles (23). 
 
The objective of this study, therefore, was to test how biaxial strain anisotropy 
independently controls fibroblast cell phenotype and matrix remodeling in 3-D 
environments. We developed and implemented a novel cyclic biaxial strain bioreactor 
with controllable homogeneous strain field anisotropy for engineered tissue hydrogels. 
We hypothesized that valvular interstitial cells (VICs) would align with respect to the 
principal directions of strain and rapidly remodel the underlying matrix to mirror this 
alignment pattern. We first determined the temporal changes in cell and matrix fiber 
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reorganization with strain anisotropy, followed by quantification of cell proliferation, 
apoptosis, and fibroblast phenotype. 
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MATERIALS AND METHODS 
Bioreactor design and optimization 
Our challenge was to create a bioreactor test system that enabled fabrication 
and stable anchoring of 3-D hydrogels, while applying a controlled multiaxial 
mechanical stimulation without having to disturb the tissue. We hypothesized that if 
elliptically shaped 3-D hydrogels were stretched uniformly along their outer 
perimeters, then the internal strain field would be homogeneous but biaxial. To 
evaluate this, finite element simulations (FEA, ANSYS Inc.) were first conducted to 
optimize geometric parameters for the bioreactor system. 20,000 prismatic rectangular 
elements were used with large strain hyperelastic (Mooney-Rivlin, modulus = 1 MPa) 
material properties performed on quarter-symmetric circular sections of silicone slab 
and platen. Both elliptical and circular slabs and/or platens were tested, with radii 
between 0.5 and 2 in. Platen/cassette hole diameter ratios were varied between 0.5 and 
0.9. Slab thickness was varied from 2 to 6 mm, with well depth ratios ranging from 0.5 
to 0.9. Finally, well centroid within the slab was translated radially from concentric to 
75% of the platen radius. Design optimization criteria were to (1) maximize the 
number of samples testable within one cassette well, (2) maximize the size of samples 
testable, (3) maximize the depth of the PDMS wells, (4) maximize the possible applied 
strain magnitude, and (5) minimize the stress developed in the PDMS. 
 
To fabricate these different hydrogel 3-D geometries, we developed thick 
elastomeric slabs instead of commonly used thin membranes (described below), which 
were secured between two circular aluminum flanges of a cassette (Fig. 7.1A). Each 
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cassette contained four cylindrical holes (where the slabs were exposed) positioned 
concentrically over Teflon lined platens. Negative molds were machined from 
polycarbonate such that small wells would be present within the silicone slab spanning 
the cassette holes above the platens (Fig. 7.1B). Molds were designed with ellipsoidal 
wells of major/minor axis ratios (hereafter Xand Y respectively) of 1:1, 2:1, and 4:1. 
Beveled edges were machined within the ellipse to ensure uniform vertical strain 
fields through the well edges and to secure a compression spring (Lee spring) for 
anchoring hydrogels. Polydimethylsiloxane (PDMS Sylgard 184, Dow Corning) was 
formed at a concentration of 20:1, degassed, poured into the negative molds, and 
solidified at 70 °C for 12 h. Slabs were then released from the molds, mounted within 
the aluminum cassettes, and autoclaved before use (Fig. 7.1C). The stage was 
constrained to vertical motion using shafts with linear bearings. A rotary stepper motor 
(34Y, Anaheim Automation) drove vertical translation through a screw-pinion gear 
assembly (Fig. 7.1D). Limit switches were mounted on either side of the translation 
stage to prevent overstrain and semi-automate calibration. A cold plate (CP12, Lytron) 
was placed underneath the stepper motor for heat transfer. Strain magnitude and 
frequency waveforms were applied to the motor via a controller module and custom 
software (DPN10601, Anaheim Automation). 
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Fig. 7.1. Design of the anisotropic biaxial strain (ABS) bioreactor.  
(A) Conceptual schematic showing a cross-sectional view of a constrained collagen 
construct embedded in a silicone slab and loaded within an aluminum cassette. (B) An 
inverted polycarbonate negative mold with machined circular and elliptical wells used 
for constructing the silicone slab. (C) An expanded view of the elliptical well 
containing elliptical compression springs. (D) Macroscopic view of the bioreactor 
containing four cassettes and 16 independent wells. 
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3-D hydrogel formation 
Collagen hydrogel 3-D tissue constructs were created using a procedure from 
one previously described (24). Briefly, porcine aortic leaflets were harvested from a 
local abattoir and valvular interstitial cells were isolated immediately (25). For these 
experiments, 400,000 cells/ml at P4-P6 were suspended in 3× DMEM with 10% FBS 
(Gibco), 2 mg/ml type I collagen (BD), and 0.1 M NaOH added to neutralize the 
solution. Depending on the geometry (ratio of major to minor axis) of the well, 
different volumes of gel were added. For the 1:1, 2:1, 4:1, and control wells, 100 µl, 
125 µl, 150 µl, and 125 µl respectively of gel was inoculated into the wells containing 
the compression springs. Gels solidified after 60 min, after which additional culture 
medium was added to the reservoir. The experimental controls consisted of a 
mechanically stressed but non-strained gel (anchored isotropic static) and a free-
floating gel (unanchored isotropic state). As in other studies(26) and (27), hydrogels 
were cultured for 24 h prior to experiments, allowing the VICs to spread and compact 
the matrix around the springs to create a flat 3-D tissue. 
  
Strain field calibration 
Marker fields (40 µm glass beads) were placed along the well bottom, gel 
surface, and at the compression spring attachment points (Fig. S7.1). The stage was 
translated to different depths, and marker positions within multiple wells were imaged 
and digitally recorded using ImageJ. Assuming uniform deformation within small 
groups of three points, the local normal and shear strain field could be described by a 
system of equations as previously described (22) (see Supplementary material for 
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more details). Comparing multiple marker groups determined strain field 
homogeneity. At least three independent point groups were compared per well and 
experimental condition for calibration. For frequency response mapping, linear 
acceleration/deceleration-time commands of increasing magnitude and shorter time 
intervals were sent to the stepper motor, creating sinusoidal stage motion patterns. 
Peak sustainable frequencies were recorded for each applied strain magnitude 
(equiaxial configuration). 
 
Biaxial strain experiments 
We equalized all applied strain fields according to the apparent area strain 
experienced by the cells by the following formula: 
 
 A/Ao = λXλY = (2EXX+1)0.5(2EYY+1)0.5 (1) 
 
where A is the current area, Ao is the initial area, λX is the stretch ratio in 
the X direction, λY is the stretch ratio in the Y direction, and EXX/EYY represent the 
principal strains in the XX and YY directions, respectively. We designed all biaxial 
strain profiles such to maintain a 20% area strain, thus only the effects of strain field 
anisotropy were tested. 3-D cultures with 1:1, 2:1, and 4:1 aspect ratios were stretched 
at 20% area strain, 1 Hz frequency for up to 96 h. Upon completion of the 
experiments, gels were removed from the springs and subjected to quantitative 
endpoint assays. 
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Quantification of cell and matrix architecture 
We quantified changes in cell orientation and matrix fiber reorganization at 48 
and 96 h via multiphoton microscopy. Image stacks of the collagen hydrogels were 
taken from the central region of each well at 5 µm vertical steps. Z-stacks 
encompassed at least 80% of the gel thickness in each sample, but were limited by the 
penetration depth of laser microscopy and slight differences in hydrogel compaction. 
Cell orientation angle distributions within each gels (0° representing the X direction) 
were determined using f-actin staining (Sigma) and quantified from maximum 
intensity projections images using ImageJ as previously described (28). We manually 
traced the shape of hundreds of cells across multiple sections for each sample, and 
organized them within a histogram to enable comparison with the fiber alignment data. 
Alignment angle distributions from each gel were normalized to the most common 
alignment angle, which was assigned a value of 1. Simultaneously, collagen fibril 
alignment angle distributions were captured using second harmonic generation (SHG) 
imaging using a custom-built nonlinear laser scanning microscope employing 
1040 nm, 1 MHz, 300 fs pulses from a Yb-fiber chirped pulse amplifier (FCPA 
µJewel D-400, IMRA America Inc.) as previously described (29). Similar to the 
cellular orientation quantification, fiber angle distributions within gels (0° representing 
the X-direction) were determined using central region Z-stacks and the maximum 
intensity projections images processed using ImageJ. ECM fibers were analyzed in 
total using an alignment algorithm (adapted from Ref. (30)) that assessed second 
harmonic generation autofluorescence (30). We observed no variation in histogram 
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profiles with relative z-axis position, and therefore pooled all the data into single 
histograms for each construct. 
 
Proliferation and apoptosis assays 
5-Bromo-2′-deoxyuridine (BrdU) incorporation was used to detect 
proliferating cells. BrdU labeling reagent (Invitrogen) was added to the culture media 
12 h prior to experiment termination (48 h). Hydrogel constructs were fixed and 
targeted with a monoclonal Anti-BrdU Alexa Fluor 488 conjugate (PRB-1, 
Invitrogen). Total DNA was counterstained using a DRAQ-5 (Biostatus) far red 
nuclear dye. TUNEL (Apo-Brdu TUNEL assay kit, Invitrogen) was used to detect 
apoptotic cells. 48 h stretch and control hydrogels were fixed and stained for disrupted 
DNA targeted by incorporation of terminal deoxynucleotidyl transferase (Tdts) and 5-
bromo-2′-deoxyuridine 5′-triphosphate (BrdUTPs). Monoclonal Ani-BrdU Alexa 
Fluor 488 conjugate was used to target the fragmented DNA and a propidium iodide 
counter stain was used to determine total cellular DNA. Positive fluorescent areas for 
each cell were measured using ImageJ and normalized by cell nuclei. 
 
VIC phenotype 
Alpha smooth muscle actin (gene name ACTA2, marker of myofibroblastic 
phenotype) and vimentin protein expression (VIM, indicative of quiescent fibroblast 
phenotype) were compared across strain conditions at 48 h using quantitative real-time 
PCR (RT-PCR, see supplemental methods) and immunohistochemistry. Antibody 
staining was performed as previously described (22). Image Z-stacks (10 µm intervals) 
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were taken with laser confocal microscopy (TCS or Leica LSM510) at fixed gain, 
offset, and averaging settings. Each label occupied a different fluorescence channel, 
and excitation lasers were sequentially activated to negate signal bleed. Z-stacks were 
taken at 5–10 µm sections and converted into maximum projections. Positive 
fluorescent areas for each color were measured using ImageJ and normalized by cell 
nuclei. Data was related as percentage of cells with cytoskeletal signal and compared 
across conditions. 
 
Statistics 
At least six samples per time point and treatment condition were used in each 
endpoint assay for statistical analysis. One-way ANOVA with Tukey’s modified post 
hoc tests were used to compare differences between means and data were transformed 
when necessary to obtain equal sample variances. For proliferation/apoptosis studies, 
statistical tests were implemented across treatment conditions and results are 
expressed as mean ± standard error. For gene/protein expression studies, statistical 
tests compared individual genes across treatment conditions and results are expressed 
as mean ± standard deviation.P < 0.05 denoted statistical significance.
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RESULTS 
Design and optimization of the anisotropic biaxial strain (ABS) bioreactor 
3-D collagen gels could be anchored within cyclically deforming wells through 
compression springs whose lengths were adjusted to press fit inside the outer edge of 
the well and were secured with a 60° beveled edge (Fig. 7.1). Preliminary finite 
element simulations determined that the major and minor axis lengths of an ellipsoidal 
well shape could independently control XX and YY strain magnitudes (Fig. S7.2A). 
Thus, by varying the eccentricity of the elliptical well, the biaxial strain profiles scaled 
with the major to minor axis ratio (Fig. 7.2). Further simulations were done to 
characterize well placement within the PDMS slab and dependence upon equiaxial 
well diameter. Using a 1:1 geometric ratio, we found that deviations in the placement 
of the well, up to 60% (25 mm) along the platen radius, did not significantly affect 
strain magnitude (Fig. S7.2B). It was also determined that the strain magnitude 
inversely correlated with well diameter, such that a reduction of 20–10% radial strain 
occurred when increasing well diameter from 2 to 8 mm (Fig. S7.2C). Finally, 
parametric optimization through finite element simulations predicted that for 50 cm 
diameter cassette holes and 6 mm wells, a silicone slab of 3/8″ thickness with 3 mm 
deep wells achieved a uniform 50% strain during 1 cm of stage translation. In this 
configuration, four holes could be fabricated in each cassette, and four cassettes could 
be secured on the translating stage. For these experiments, however, one well was 
created at the center of each cassette hole. 
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Fig. 7.2. Calibrated strain fields overlaid with FEA simulations.  
(A) 1:1 circular well introduced an equiaxial strain field with minimal shear captured 
by FEA simulations. (B) 2:1 ellipsoidal well introduced a biaxial strain field captured 
by the FEA simulations. (C) 4:1 ellipsoidal well introduced a biaxial strain field that 
was slightly overestimated by the FEA simulations. (D) Strain vs. frequency curves 
for the 1:1 geometry indicates the ability to generate large deformations at high 
frequencies. Error bars show ±SD. N ⩾ 6 samples for each geometry and strain 
magnitude condition.   
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We next compared our FEA simulations against measured strains of 3-D 
tissues within different elliptical well geometries. Stretching a 1:1 geometry 
introduced strains exceeding 25% ± 0.6% resulted in no significant differences 
between EXX and EYY (Fig. 7.2A). Conversely, a 2:1 geometry created homogeneous 
biaxial strain fields of at least 20% ± 1.8% in the EXX and 42% ± 2.1% in 
the EYY directions, with negligible shear strain. The applied EXX/EYY strain ratio was 
consistently 2:1 regardless of applied strain magnitude or loading cycle (Fig. 7.2B). 
Stretching 4:1 geometries introduced strains exceeding 9.1% ± 1.1% in the EXX and 
39% ± 1.2% in the EYY, with a nearly consistent 4:1 magnitude ratio (Fig. 7.2C). 
Experimental results confirmed FEA predicted nonlinear increases in applied biaxial 
strain magnitudes with stage translation. For all gel ratios, shear strain EXY varied 
between 0 ± 1.5% at the maximum loaded conditions and can be considered not 
statistically different from zero strain. We next determined the maximum stable strain 
magnitude as a function of frequency (Fig. 7.2D). For equiaxial profiles, a maximum 
strain of 27%, 18%, 12%, 8% and 5% was achieved at 1, 2, 3, 4 and 5 Hz, 
respectively. Peak biaxial strain magnitudes in the YY direction were higher at each 
frequency, but proportional to the area strain during equiaxial loading. Collectively, 
these results establish and validate a unique and versatile high-throughput anisotropic 
biaxial strain bioreactor system for planar 3-D tissue cultures. 
 
Biaxial strain anisotropy regulates cellular apoptosis and proliferation 
VICs seeded 3-D collagen hydrogel constructs were strained at 20% area 
strain, with varying biaxial anisotropies at 1 Hz, and static cultures served as controls. 
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To verify that our bioreactor was able to maintain viable cells for at least 96 h, we 
performed a live/dead (green/red) assay on the hydrogel constructs. The percentage of 
live cells in the 1:1 (89% ± 1.3%) and 4:1 (86% ± 0.9%) geometries decreased with 
anisotropy compared to the percentage in anchored controls (91% ± 0.9%), but were 
consistently above 85% viability (Fig. 7.3A–E). At 48 h, the number of apoptotic cells 
(yellow) in the 2:1 (8.5% ± 0.3%) and 4:1 (9.6% ± 0.5%) geometries increased 
relative to anchored controls (5% ± 0.2%) (Fig. 7.3F–J). This result suggests that cell 
death is largely driven by strain-induced apoptosis rather than bioreactor cytotoxicity. 
An increase in cell proliferation was also visually apparent for the mechanically 
stimulated conditions at 48 h. Using BrdU labeling, we found that with increasing 
biaxial anisotropy, the number of proliferative cells (green) in the 1:1 (26% ± 1.9%), 
2:1 (34% ± 1.4%), and 4:1 (37% ± 1.1%) geometries statistically increased relative to 
anchored controls (16%, ± 1%) (Fig. 7.3K–O). These findings suggest biaxial strain 
anisotropy enhances both cell proliferation and apoptosis, suggestive of an actively 
remodeling microenvironment. 
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Fig. 7.3. Apoptosis and proliferation correlate with increasing biaxial anisotropy 
at 48 h.  
(A–D) Live/dead assay reveals an increasing amount of dead cells with increasing 
biaxial anisotropy (live – green, dead – red). (E) Quantification of dead cells as a 
percentage of total cells. (F–I) Apo-BrdU assay reveals an increasing amount of 
apoptotic cells with increasing biaxial anisotropy (apoptotic–yellow, DNA – red). (J) 
Quantification of apoptotic cells as a percentage of total cells. (K–N) BrdU labeling 
assay reveals an increasing amount of proliferative cells with increasing biaxial 
anisotropy (proliferative – green, DNA–blue). (O) Quantification of proliferative cells 
as a percentage of total cells. Error bars show ± SE, N ⩾ 6 samples per test condition. 
ANOVA with Tukey’s post hoc testing determined statistical significance atp ⩽ 0.05 
thresholds. Bars that do not share letters are significantly different from each other. 
166 
Cell and matrix fibers rapidly reorient orthogonally with cyclic strain anisotropy 
At 48 h, significantly more f-actin labeled cells were found in cyclically 
stretched compared to the statically anchored controls, which partly reflects both 
increased matrix compaction and proliferation (Fig. S7.3A–D). Static controls and 1:1 
equiaxial strain revealed random orientations of cells denoted by the cytoskeletal (f-
actin) filaments (Fig. S7.3E and F). Normalized cell and matrix alignment index 
distribution curves indicate that orientation along the major X (0°) and minor Y (90°) 
axes was maintained throughout a 0.3–0.8 range (Fig. S7.3M and N). In contrast, the 
2:1 and 4:1 geometries revealed a cross-hatched network of cells aligning along the 
major and minor axes with greater cross-alignment in the 4:1 geometry (Fig. S7.3G 
and H). Normalized alignment curves indicate that alignment along the major and 
minor axes ranged from 0.90 to 0.95 and 0.50 to 0.40, respectively, while the 45° 
orientation dropped to a lower fraction of 0.1–0.2 (Fig. S7.3O and P). Second 
harmonic generation imaging of collagen fibrils showed a lack of fibril alignment 
regardless of strained condition (Fig. S7.3I–L, M–P). At 96 h, static controls and 1:1 
cyclic equiaxial strain revealed random orientations of cells denoted by the 
cytoskeletal (f-actin) filaments (Fig. 7.4A–B, E–F). Normalized cell and matrix 
alignment index distribution curves indicate that orientation along the major X (0°) 
and minor Y (90°) axes was maintained throughout a 0.4–0.8 range (Fig. 7.4M and 
N). In contrast, the 2:1 and 4:1 geometries revealed a cross hatched network of cells 
aligning along the major and minor axes with greater cross-alignment in the 4:1 
geometry (Fig. 7.4C–D, G–H). Normalized alignment curves indicate that alignment 
along the major and minor axes ranged from 0.85 to 0.95 and 0.55 to 0.35, 
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respectively, while the 45° orientation dropped to a lower fraction of 0.1–0.2 (Fig. 
7.4O and P). Likewise, second harmonic generation imaging of collagen fibrils 
showed a similar trend such that increasing degrees of fibril alignment occurred with 
increasing anisotropic strain (Fig. 7.4I–L, M–P). Taken together, VICs rapidly 
reoriented within 48 h of cyclic strain and maintained orientation through 96 h. 
Extracellular matrix architecture, on the other hand, was poorly aligned at 48 h 
regardless of the applied strain field as determined by SHG, suggesting that cell 
orientation precedes fiber alignment. Collectively, these results demonstrate that 
applied cyclic biaxial strain anisotropy drives rapid VIC cell orientation and matrix 
fiber alignment in a temporally regulated manner, with cell reorientation leading 
extracellular matrix remodeling. 
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Fig. 7.4. Cell and matrix fibers rapidly reorient orthogonally with cyclic strain 
anisotropy at 96 h.  
(A–D) Macroscopic view of collagen gels compacted within elliptical compression 
springs. (E–H) Orientation of VICs associated with the anisotropic strain profiles (f-
actin-green). (I–L) Orientation of collagen fibrils associated with anisotropic strain 
profiles (SHG imaging). (M–P) Representative alignment curves indicate orientation 
of both VIC and collagen fibrils coincide and align with respect to the principal 
directions of strain. However, a larger degree cellular orientation and fiber alignment 
occurs perpendicular to the first principal strain direction (Y). 
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Valve interstitial cell phenotype is modulated by biaxial strain anisotropy 
Alpha-smooth muscle actin (ACTA2) is a key cytoskeletal filament involved 
in many myofibroblastic phenotype behaviors. Within unanchored 3-D hydrogel 
cultures (free floating), VICs express low amounts of ACTA2. However, when 
cultured under anchored conditions (mechanically constrained), ACTA2 gene 
expression increased (2.87 ± 0.13 of control), indicating that tissue stress enhances 
myofibroblastic differentiation (Fig. S7.4). After 48 h of stretch at either the 1:1 or 2:1 
geometries, ACTA2 gene expression was significantly downregulated with respect to 
anchored unstrained controls (expression 0.27-0.32 ± 0.05 fold of anchored control, no 
difference between). Stretch at the 4:1 geometry nearly doubled the amount of ACTA2 
expression compared to equiaxial strain, but still less than half of the static anchored 
condition (0.47 ± 0.04 of control) (Fig. 7.5A). Vimentin (VIM) expression was 
insensitive to unanchored vs. anchored conditions (Fig. S7.4), but was significantly 
downregulated within the 1:1 or 2:1 geometries (0.62 ± 0.07 and 0.59 ± 0.13 
respectively, no difference between). Stretch at the 4:1 geometry significantly 
increased VIM expression (1.13 ± 0.18 fold), recovering to control expression levels 
(Fig. 7.5A). These same trends were confirmed at the protein level via 
immunofluorescence (Fig. 7.5B–F). ACTA2 protein was downregulated significantly 
under equiaxial strain (0.61 ± 0.07) and slightly increased with the 4:1 geometry 
(0.76 ± 0.05). VIM was downregulated with equiaxial strain (0.76 ± 0.08) and then 
returned toward unstrained control levels with the 4:1 geometry (0.87 ± 0.06) (Fig. 
7.5G). Interestingly, a preponderance of cells oriented parallel to the gel major axis 
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(thus perpendicular to the greater strain direction) expressed ACTA2 protein in the 4:1 
geometry (Fig. 7.5F). Together, this suggests that cyclic strain anisotropy 
independently contributes to VIC fibroblast–myofibroblast differentiation tendencies. 
Equibiaxial to mildly anisotropic stretch decreases ACTA2 and VIM gene and protein 
expression, while more dramatic strain anisotropy increases both ACTA2 and VIM 
expression. 
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Fig. 7.5. Biaxial strain anisotropy modulates fibroblast cell phenotype at 48 h.  
(A) Gene expression was measured via real-time PCR, normalized to 18S, and 
expressed relative to unstretched anchored gel controls. ACTA2 gene expression 
decreased in all strain conditions, while VIM gene expression returned to control 
levels with 4:1 biaxial directionality. (B–F) ACTA2 (green) and VIM (blue) protein 
expression were measured via immunofluorescence with DNA (red) counterstain. (G) 
Quantification of total fluorescence was normalized to cell number and compared 
relative to unstretched control gels. (F) Although ACTA2 expression reduces with 
cyclic stretch, cells orienting perpendicular to the major axis of stretch expressed 
increased ACTA2 in the 4:1 geometry. Error bars show ± SD, N ⩾ 6 samples per 
strain geometry and protein. Bars that do not share letters are significantly different 
from each other as determined by one-way ANOVA with Tukey’s post hoc (p ⩽ 0.05). 
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DISCUSSION 
Anisotropic strain in vivo and in vitro 
Many planar connective tissues exhibit heterogeneous matrix fiber orientations 
that dictate anisotropic biomechanical properties which are critical for proper function. 
As an example, aortic heart valve cusps are very compliant in the radial direction but 
stiff in the circumferential direction, which greatly assists in efficient Coaptation and 
rapid opening during the cardiac cycle. Simultaneous mechanical testing and collagen 
fiber distribution profiling demonstrates that anisotropic fiber splay and reorientation 
is a key contributor to physiological valve function (31) and (32). In altered loading 
environments, such as in hypertension or congenital malformation (e.g. bicuspid aortic 
valve), local cell and matrix architecture is modified with an increased risk of tissue 
degeneration (33), (34), (35) and (36). Greater understanding of how strain field 
anisotropy controls fibroblast cell phenotype and matrix remodeling has been 
challenging to study in vivo due to the confounding complexity of multiple 
interrelated biological signals and inherent tissue variability. Applying anisotropic 
strains within well-controlled 3-D culture systems has been limited by (1) an inability 
to prescribe strain magnitudes in orthogonal directions independently, and (2) 
difficulties in anchoring 3-D engineered tissues within bioreactors without 
compromising the homogeneity and consistency (over time) of the applied strain. 
Pneumatic actuator based elastomeric substrate deformation is commonly applied but 
rate-limited by the compressibility of air, rarely exceeding 1.5 Hz for physiological 
soft tissue strains. Alternatively, mechanical cams require constant adjustment and 
repeat calibration (20) and (37). Biaxial stretching of hydrogels was recently 
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performed by molding hydrogel constructs in a cross pattern within a rotating 
cam (38). However, the applied strain field was inhomogeneous and difficult to 
monitor over time. Furthermore, hydrogels can be adhered to elastomeric substrates 
via adhesive proteins, but the magnitudes of strain applicable are limited (22). The 
design presented in this study overcomes these limitations by (1) prescribing strain 
anisotropy through eccentricity of the culture well geometry, and (2) providing 
uniform and stable construct attachment via compression springs. We were able to 
apply homogeneous large deformation strain profiles (>30%) at high frequencies 
(3 Hz) to engineered 3-D tissues for at least 96 h, significantly broadening the scope of 
3-D in vitro mechanobiological inquiry available. 
 
Anisotropic mechanoregulation of VIC phenotype 
Fibroblasts transition between quiescent and activated myofibroblasts, which is 
controlled in part by the local mechanical environment. In the case of aortic valves, 
interstitial cells are largely quiescent fibroblasts in healthy tissue, but can become 
activated myofibroblasts and even osteoblasts in disease states (39), (40) and (41). 
Taylor et al. defines the quiescent valve fibroblast phenotype as one that maintains 
ECM composition and collagen maturity (42). When VICs become activated 
myofibroblasts, they significantly upregulate contractile filaments including ACTA2, 
exhibit increased traction forces and migratory behavior, and secrete matrix proteins 
as well as their proteases and inhibitors. These factors all lead to dramatic changes in 
matrix composition and structural organization (39) and (42). Grinnell et al. and 
colleagues have used free floating (stress-free) and anchored (stressed) collagen 
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hydrogels to show that matrix tension induces a myofibroblastic differentiation of 
fibroblasts from a variety of sources (6), (43) and (44). We previously found that VICs 
cultured in 2-D flasks expressed nearly double the amount of ACTA2 when compared 
to seeded within floating3-D collagen gels, supporting this concept (45). Similarly, we 
here find that mechanically anchored VICs in 3-D culture expressed ACTA2 nearly 
three times higher than unstressed controls (Fig. S7.4). Taken together, these results 
suggest that VICs in anchored 3-D collagen gels provide a simple positive-control 
model of myofibroblast-like differentiation. 
 
Fibroblast–myofibroblast transitions of VICs in the context of cyclic stretch, 
however, are more complex. Merryman et al. showed that cyclic uniaxial stretch of 
porcine aortic valve leaflets for 7–14 d produced a slight increase in ACTA2 gene 
expression, but a marked increase with exogenous TGFβ1 administration (46). Thayer 
et al. found that increased ACTA2 expression due to cyclic stretch could be relieved 
with combined loading with cyclic pressure (47). Our findings here, using VICs in 3-D 
hydrogel culture, show that ACTA2 expression is also independently regulated by the 
anisotropy of applied cyclic strain. Cyclic equiaxial strain decreases ACTA2 
expression, suggesting fibroblast-like tendencies, but strong directional biaxial strain 
re-elevates ACTA2 toward the stressed myofibroblastic control condition. We further 
found that ACTA2 expression was directly related to the degree of cell alignment, 
which occurred perpendicular to the first principal axis of stretch. Vimentin, 
commonly employed as a marker for fibroblasts, is an intermediate filament expressed 
by mesenchymal cells and responsible for cytoskeletal integrity, but not expressed 
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exclusively by fibroblasts (48). We found vimentin expression changed similarly with 
ACTA2 under cyclic stretch, but there was no change between anchored and free-
floating 3-D gels, nor we did not notice a directionally dependent expression tendency 
like we did with ACTA2. Therefore, we are confident that vimentin was a reasonable 
choice as a fibroblast marker for this system, and focus our interpretations on ACTA2 
and other behaviors. 
 
Our results here demonstrate that the complete picture of fibroblast 
“quiescence” and “activation” should also include cell phenotype and turnover 
characteristics. Schnieder and Deck et al. used autoradiographic labeling in rats to 
demonstrate that normal cell and matrix turnovers in a variety of fibroblast-populated 
tissues are not identical. In fact, valve leaflets exhibited naturally elevated 
proliferation, matrix synthesis, and degradation rates indicative of a continuous but 
homeostatic remodeling environment (7). Considering that the native healthy valve 
contains relatively few myofibroblasts, this suggests that phenotype “quiescence” may 
still present dynamic matrix remodeling behavior. Our studies here suggest that one 
factor that can potentiate this is mechanical forces, specifically anisotropic cyclic 
stretch. Cyclic biaxial strain induced both VIC proliferation and apoptosis, suggesting 
a high degree of turnover, while equiaxial strain exhibited significantly less. 
Furthermore, equiaxial strain had very little effect on matrix fiber reorganization, 
while cyclic anisotropic strain resulted in significantly aligned matrix fibers. 
Following this trend, equibiaxial stretch reduced ACTA2 expression, while anisotropic 
strain elevates it. Taken together, these results suggest that cyclic equiaxial strain 
177 
promotes a tendency towards a quiescent fibroblastic phenotype, and increasing strain 
anisotropy supports a tendency towards an active myofibroblastic differentiation. We 
note that all these studies were performed at the same overall magnitude of area strain 
and frequency. While not the focus of this study, we believe that these responses are 
likely further altered by strain magnitude and frequency (49). It appears that matrix 
remodeling lags changes in cell response to anisotropic strain, but the underlying 
cause is not yet known. Without live cells, however, no matrix fiber alignment occurs 
in any strain pattern (data not shown), suggesting that this remodeling is an active cell-
mediated response to the applied strain field. Future studies considering altered matrix 
synthesis, degradation, or matrix fibril diameter, may help reveal the time-dependent 
remodeling tendencies and clarify the extent of differentiation. 
 
Accelerated tissue engineering via strain anisotropy 
Modern tissue engineering approaches for load-bearing tissues have sought to 
mimic or restore the native biological and biomechanical characteristics of replaced 
tissue, among them biomimetic material anisotropy (50). Fiber-reinforced scaffolds, 
whether electrospun, nonwoven, or woven mesh designs with biodegradable materials 
have been employed to create directionally dependent material behaviors (51). 
Alternatively, biological polymers such as collagen and fibrin can be mechanically 
stimulated to evolve material heterogeneity (52) and (53). Whether this anisotropy 
needs to be included at the outset or evolved over time is still debated. Many 
bioreactors designed for whole tissues expose local regions to anisotropic strain fields, 
but these are difficult to quantify and challenging to relate directly to local cell 
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differentiation and matrix remodeling (54). Alternatively, anisotropic mechanical 
conditioning of 3-D engineered tissue sheets could accelerate the formation of desired 
structural architecture and tissue biomechanics prior to forming more complex tissue 
shapes (55). Furthermore, our results suggest it may be possible to direct 
stem/progenitor cells towards multiple distinct phenotypes through strain anisotropy, 
which has a potential advantage in that these cells will also be self-organized in their 
environmental context. It is not yet known how cells in defined 3-D matrix 
architectures interpret both time and directionally varying anisotropic strain fields, but 
our findings suggest that each component may contribute to accelerated matrix 
remodeling and cell differentiation. 
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CONCLUSIONS  
We developed and implemented a novel bioreactor to investigate the 
relationship between anisotropic strain, cell differentiation, and matrix remodeling in 
3-D culture. Our findings demonstrate that applied cyclic biaxial strain anisotropy 
induces time-dependent VIC orientation and collagen fiber alignment, which occurs at 
48 h and 96 h, respectively. During this process, ACTA2 expression was directly 
related to the degree of cell alignment and occurred perpendicular to the principal axes 
of loading. These findings suggest that biaxial strain anisotropy, independent of 
magnitude or frequency, is a potent regulator of rapid matrix reorganization and VIC 
phenotype. Controlling strain anisotropy in vivo or in vitro may be a potent means of 
directing adaptive tissue remodeling. 
.
180 
SUPPLEMENTARY DATA 
SUPPLEMENTAL METHODS 
Cell Isolation  
Adult PAVIC were isolated by a collagenase digestion method as previously 
described.  Briefly, aortic valve leaflets were obtained from a local abattoir and placed 
on cold Dulbecco’s phosphate buffered saline (Invitrogen) for transport.  The surface 
of the leaflets was partially digested in (600U/ml, Worthington) collagenase solution 
with Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco) for 5-10 minutes after 
which the endothelial layer was sheared off with a cotton swab.  The remaining leaflet 
was then incubated for 12-18 hours in collagenase solution and homogenized with a 
serological pipette.  Cells were then plated on tissue culture plastic, and maintained 
with DMEM (Gibco) supplemented with 10% fetal bovine serum (Gibco) and 1% 
penicillin/streptomycin (Gibco).  Cultures were fed every two days and split at 
confluency.  Cultures used for experiments were between passages 4 and 6. 
 
Strain Calibration Equations  
These patterns related the undeformed (unstrained) configuration and the 
deformed (strained) configuration by position , namely: 
 
 !! = !!! + !!  Equation (1) 
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where x is the deformed coordinates, and X  is the undeformed coordinates. F is a 
deformation gradient tensor for the plane of interest, either membrane or construct 
surface: 
 
 !!" = !!!!!!  Equation (2) 
 
By solving the system of equations in Eq. (1) relating the observed deformed and 
undeformed configurations of triangular bead/mark positions, the coefficients of F 
were obtained. These were then was used to obtain finite (Green’s) strain components: 
 
 ! = 0.5 !!! − !   Equation (3) 
 
where I is the identity tensor. Finite strain was then transformed into area strain by the 
following formula:  
 
 !!! = !!!! = 2!!! + 1 !.! 2!!! + 1 !.!  Equation (4) 
 
Anisotropic Strain of 3D Tissue Constructs  
The device used to impose anisotropic strain is a modified version of the 
system described in detail by Butcher et al.  The system consists of four aluminium 
cassettes which are placed on a movable stage, and clamped concentrically over a 
rigid aluminium cylindrical mandrel lined with Teflon.  A stepper motor (34Y, 
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Anaheim Automation) was used to drive the movable stage down over the rigid 
mandrel deforming the silicon membrane at a specific magnitude and frequency.  
Limit switches were mounted on either side of the movable stage so that any unwanted 
movement would be controlled.   These modifications only require one calibration of 
the wells and re-zeroing is recognized by the limit switches.  A cooling system was 
also implemented to control the temperature from the stepper motor to the surrounding 
metal.  A cold plate (CP12, Lytron) was mounted below the stepper motor connected 
to a stand up freezer contained cold water.  The cold water from the freezer was 
pumped to the cold plate and returned the heated water from the stepper motor.  The 
magnitude and frequency of the stepper motor was controlled through a controller 
(DPN10601, Anaheim Automation) and various waveforms could be applied 
depending on the duration of current applied. 
 
Construction of Cassettes  
To create the silicon membranes used for straining the hydrogels, a negative 
mold within 3/8” piece of polycarbonate was constructed (Fig. 1B).   The 
polycarbonate was machined to form wells at a depth of 3mm, at various biaxial 
eccentricities.   In terms of major to minor axis (x vs. y), ellipsoidal wells were 
generated at 1:1, 2:1, and 4:1 geometries.  A bevel was also machined within the 
ellipse for securing the compression springs.  Polydimethylsiloxane (Sylgard 184, 
Dow Corning, Midland, MI) was combined at a concentration of 20:1 respectively, 
and degassed prior to use.  The silicon was poured into the negative molds and let 
solidify at 70°C for 12 hours.  The silicon molds were then released from the 
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polycarbonate, mounted within the cassettes, and autoclaved.  The sterilized 
compression springs were then placed in the wells and covered with a petri dish lid 
(150mm).  
 
FEA Analysis 
Throughout the design of the bioreactor, a finite element model was used to 
optimize shapes and ensure homogeneous anisotropic strain patterns.  Various well 
diameters, aspect ratios, silicon membrane depths, cassette sizes, magnitudes of strain, 
and frequency were all considered.  The silicon membranes were modeled as a 
hyperelastic material using a Mooney-Rivlin two-parameter model with invariant 
coefficients of 0.55 and 0.14 MPa.  The membranes were first generated within the 
plane function as 2D triangular elements.   The geometry of membrane measured 
25mm in radius and the platen was 20mm in radius with a filet radius of 1mm.  
Contact analysis using a sliding boundary condition was used for the intersection 
between the membrane and platen, assuming a   coefficient of friction of 0.06 (Castrol, 
Braycote 803).  For all simulations, the displacement was applied to the edge of the 
membrane.  All finite element simulations were completed through ANSYS.IN 
 
Hydrogel Seeding 
Three-dimensional (3D) hydrogel constructs were created using a modified 
procedure from that previously described.  Porcine aortic valve interstitial cells 
(PAVIC) were used as a representative planar tissue fibroblast source.  A suspension 
of 400,000 cells/ml porcine aortic valvular interstitial cells (PAVIC) were used in 3x 
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DMEM with 10% FBS (Gibco), 2 mg/ml type I collagen (BD), and 0.1 M NaOH to 
neutralize the solution.  3D cultures with 1:1, 2:1, and 4:1 aspect ratio were pre-loaded 
300 steps below center of platen.  This was done to shift the calibration curve to the 
linear portion of the graph and increase the size of the well.  Once pre-loaded, wells 
were filled with different volumes of gels depending on the geometry (ratio of major 
to minor axis).  For the 1:1, 2:1, 4:1, and control wells, 100µl, 125µl, 150µl, and 
125µl respectively of gel was inoculated into the wells containing the compression 
springs, which solidified after 60 minutes.  After 60 min, 18 ml of media was added to 
the reservoir.  The hydrogels were allowed to compact around the springs over a 24 hr 
period after which a 20% area strain (250 step size, 2mm) was applied to all the 
constructs at 1Hz.  This seeded compaction process is similar to Garvin et al. such that 
fibroblasts suspended in collagen gels will compact around an anchor and form a 
stable construct .  Static cultures served as controls and both mechanically anchored 
and unanchored hydrogels were used.  The unanchored controls were lifted from the 
well after 24 hr to allow free compaction of the gels.  All materials were sterilized via 
autoclaving before use.  The system was housed in a standard tissue culture incubator, 
maintained at 37°C and 5% CO2 throughout the culture period. 
 
Second Harmonic Generation 
Galvanometric mirrors were use to scan laser pulses in a raster pattern. The 
laser scanning and data acquisition were controlled by MPSCOPE software . SHG 
signal was detected using a bandpass filter centered at 517 nm with 65-nm bandwidth.  
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Images were acquired using a 0.95-numerical aperture, 20x water immersion objective 
(Carl Zeiss Inc., Thornwood, NY) at 10 µm section spacing. 
 
RT-PCR 
To determine gene expression changes, the hydrogel construct was isolated 
from the center of each well.  Using a Qiagen total RNA purification kit (Qiagen, 
Valencia, CA), RNA was reverse transcribed to cDNA using the SuperScript III RT-
PCR kit with oligo(dT) primer (Invitrogen).  Sufficient quality RNA was determined 
by an absorbance ratio A
260
/A
280 
of 1.8 – 2.1, while the quantity of RNA was 
determined by measuring the absorbance at 260nm (A
260
). Primers were designed to 
detect 18S, alpha-smooth muscle actin, and vimentin in cDNA clones:  18S (R–
AATGGGGTTCAACGGGTTAC, F-TAGAGGGACAAGTGGCGTTC, Amplicon 
92bp, Accession DQ437859.1), VIM (F–GTACCGGAGACAGGTGCAGT, R– 
TTCCACGGCAAAGTTCTCTT, Amplicon 69bp, Accession XM_00213072.1), 
ACTA2 (F–CAGCCAGGATGTGTGAAGAA, R-TCACCCCCTGATGTCTAGGA, 
Amplicon 104bp, Accession NM_001164650.1 ).  Real time PCR was performed on 
all samples using SYBR Green PCR master mix (Applied Biosystems, Carlsbad, CA) 
and a MiniOpticon Real-Time PCR Detection System (Biorad, Hercules, CA).  
Amplification cycle thresholds were normalized to those from 18S and melt curves 
compared across samples.  Stable expression of 18S was observed across all 
mechanically stimulated conditions and GAPDH was used as a secondary 
housekeeping gene to verify expression level. 
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Collagen Gel Immunofluorescence  
Fixed samples on collagen gels were washed for 15 minutes on a rocker 3 
times with PBS, permeabilized with 0.2% Triton-X 100 (VWR International, Radnor, 
PA) for 10 minutes, and washed another 3 times with PBS. For the phenotype studies, 
samples were incubated overnight at 4oC in a 1% BSA (Rockland Immunochemicals, 
Inc., Gilbertsville, PA) blocking solution followed by another 4oC overnight 
incubation with mouse anti-human vimentin (VIM) 1:100 (Invitrogen) and rabbit anti-
human α-SMA 1:100 (Spring Bioscience).  For the orientation studies, samples were 
incubated with phalloidin (Invitrogen).  After 3 washes for 15 minutes with PBS, 
samples were exposed to Alexa Fluor® 488 or 568 conjugated (Invitrogen), species 
specific secondary antibodies at 1:100 in 1% BSA for 2 hours at room temperature. 
Three more washes with PBS for 15 minutes were followed by incubation with either 
DRAQ5 far red nuclear stain (Enzo Life Sciences, Plymouth Meeting, PA) at 1:1000 
or Hoechst (Invitrogen) at 1:10000.  Samples were washed once more with 18Mohm 
water and stored in 18mohm water at 40C. Images were taken with a Leica TCS SP2 
laser scanning spectral confocal microscope (Leica-Microsystems, Bannockburn, IL).  
ACTA2 and VIM was measured by creating a region of interest across the entire 
image.  Total intensity of F-actin (green) and VIM (blue) was quantified.  These 
values were then normalized by total nuclei within the image.  All image and 
processing settings were consistent throughout. 
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Supplement Figure 7.1 – Calibration of anisotropic strain fields.   
(A) 40 µm glass beads were placed within the collagen hydrogel and tracked from the 
undeformed to the (B) deformed configuration.  Virtual triangles created with bead 
centroids as vertexes were used to quantitatively monitor tissue deformation and to 
assess the uniformity of the strain field (inset). 
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Supplement Figure 7.2 – FEA simulations for predicted strain fields and 
geometry variations.    
(A-B) Representative 3D strain field simulations (isotropic view) for elliptical well 
configurations, plotted against both the EXX and EYY direction of radial force (red 
denotes high levels of strain where regions of blue indicate low levels).  (B) Varying 
equiaxial well position within the PDMS slab does not alter magnitudes and 
distribution of strain field such that a 20% radial strain is maintained through a 25mm 
deviation from the PDMS slab focus.  (C) Changes in equiaxial well size leads to a 
significant reduction in achievable strain magnitudes such that a reduction of 20% to 
10% radial strain occurred when increasing well diameter from 2mm to 8mm. 
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Supplement Figure 7.3 – Cell and matrix fibers rapidly reorient orthogonally 
with cyclic strain anisotropy at 48 hours.   
(A-D)  Macroscopic view of collagen gels compacted within elliptical compression 
springs.  (E-H)  Orientation of AVIC associated with the anisotropic strain profiles (f-
actin-green).  (I-L)  Orientation of collagen fibrils associated with anisotropic strain 
profiles (SHG imaging).  (M-P)  Representative alignment curves indicate orientation 
of VIC and coincide with respect to the principal directions of strain while minimal 
collagen fibril alignment has occurred. 
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Supplement Figure 7.4 - Mechanically anchored and unanchored hydrogels 
regulate ACTA2 expression levels at 48 hours.   
Mechanically anchored hydrogels elevate ACTA2 and expression levels (2.87 fold ± 
0.13) compared to unanchored hydrogels, while VIM expression is unchanged.  Gene 
expression was measured via real-time PCR and normalized to 18S. Error bars show 
±SD, n ≥ 6.  Asterisks signify statistical differences according to a Student’s t-test (p ≤ 
0.05).      
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CHAPTER 8 
CONCLUSIONS AND FUTURE DIRECTIONS 
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CONCLUSIONS AND FUTURE DIRECTIONS 
In vivo cerebral microcirculation of hematological disease states has not been 
previously investigated in detail due to a lack of suitable animal models and advanced 
imaging techniques for this research. The work in this dissertation pioneers precise, 
quantitative methods to study how alterations in blood rheology can impact cortical 
microvascular flow by taking advantage of non-linear optical microscopy techniques. 
In this final chapter, we will review the major conclusions as well as present future 
directions of our studies.  
 
The first step in our studies dealt with enhancing the temporal resolution and 
efficiency of an automated algorithm to resolve blood flow speed from images 
acquired with two-photon excited fluorescence microscopy. We developed the 
algorithm to achieve fine hemodynamics details and were able to elucidate the 
dependency of cortical blood flow in single vessels, including capillaries and venules, 
on cardiac rhythms. We also discovered decreased blood flow speed just prior to each 
inhalation—a finding that some previous studies were in agreement with, but not 
others. The measurements of cerebral hemodynamics were the first with such 
sensitivity reported thus far and will enable further in-depth, high quality studies of 
cortical circulation, a process that is critical to maintaining neuronal health and 
function. 
 
Next, we applied our technique to investigate the brains of myeloproliferative 
neoplasm mouse models. Cortical capillaries were chronically occluded in 
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polycythemic and essential thrombocythemic subjects due to the elevation of red 
blood cells, leukocytes, and platelets. Subjects with only red blood cell elevation also 
display marked stalled capillaries although not as severe as those with polycythemia. 
Activated leukocytes and platelets were found to obstruct cerebral blood flow by 
adhering to endothelium, which is injured and stimulated in a hyperviscosity flow 
regime. For blood vessels still showing flow, there is a general trend of slower blood 
flow. We investigated the effects of aspirin, a drug commonly used in essential 
thrombocythemia and polycythemia vera patients; and found minimal impacts that aid 
in reducing the disturbance of microvascular flow. Our study unearthed thrombosis in 
the microvascular network of myeloproliferative neoplasm brains, as well as identified 
leukocytes and platelets as the mechanism by which microvessels were plugged. 
These findings suggest that impediments to normal microcirculation  can lead to 
cognitive degeneration in myeloproliferative neoplasms, and furthermore they point to 
the need for careful neurological evaluation.  
 
Finally, we made use of second harmonic generation using femtosecond laser 
pulses in order to visualize collagen tissue rearrangement. Collagen is known to 
rearrange according to mechanical forces in their environment (for example, heart 
tissue demonstrates this phenomenon), but current techniques have been limited to 
equibiaxial or uniaxial stretch. Our novel bioreactor system applied anisotropic strain 
in a three-dimensional hydrogel and found increased cellular orientation and collagen 
fiber alignment along the principal directions of the strain field. Increasing biaxial 
strain anisotropy also stimulated both cellular proliferation and apoptosis during the 
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rearrangement. When cyclic strain field was applied, vimentin and smooth muscle 
actin expression rose with strain anisotropy and alignment was correlated in the same 
direction. These findings are fundamental to the design considerations and use of 
tissue engineering tools and techniques for remodeling soft tissues such as the cardiac 
muscles. 
 
This work has used novel techniques to elucidate the impacts on cerebral 
microcirculation of hematological conditions where cellular components of the blood 
are in excess. In future work, we are interested in sickled-cell disease where anemia 
and abnormal red blood cells physiology dominate rheology. This study will fulfill the 
span of blood cell concentrations—from insufficient to excessive—to gain a further 
understanding of the significant thrombotic complications that evolve as cell numbers 
diverge from a healthy state. 
